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Tankyrase1 is a multifunctional poly(ADP-ribose) polymerase that 
can localize to telomeres through its interaction with the shelterin component 
TRF1. Tankyrase1 poly(ADP-ribosyl)ates TRF1 in vitro, and its nuclear 
overexpression leads to loss of TRF1 and telomere elongation, suggesting 
that tankyrase1 is a positive regulator of telomere length. In agreement with 
this proposal, we showed that tankyrase1 RNA interference results in 
telomere shortening proportional to the level of knockdown, while a 
tankyrase1-resistant form of TRF1 enforced normal telomere length control. 
Thus, in human cells, tankyrase1 appears to act upstream of TRF1, 
promoting telomere elongation through the removal of TRF1. This pathway 
appears absent from mouse cells. We demonstrated that murine TRF1, 
which lacks the tankyrase1-binding motif, is not a substrate for tankyrase1 
poly(ADP-ribosyl)sylation in vitro. Furthermore, overexpression of 
tankyrase1 in mouse nuclei did not remove TRF1 from telomeres and had no 
detectable effect on other components of mouse shelterin. We propose that 
the tankyrase1-controlled telomere extension is a human-specific elaboration 
that allows additional control over telomere length in telomerase positive 
cells. 
TIN2 interacts with the double-stranded telomeric DNA-binding 
proteins TRF1 and TRF2 independently or simultaneously, acting as a 
bridge linking TRF1 and TRF2 to TPP1 and POT1, the single-stranded 
telomeric DNA-binding protein. To gain further insight into the function of 
the TRF2-TIN2 complex, we created a TRF2 mutant that no longer 
associates with TIN2. Employing protein overlay assays, we established that 
TIN2 binds TRF2 within its hinge domain from residues 352 to 367. 
Deletion of this region led to the production of a TRF2 TIN2-binding 
mutant, TRF2ΔT, which abrogated TRF2-TIN2 binding in protein overlay 
assays and in immunoprecipitation analysis. Expression of TRF2ΔT in MEFs 
that contain a conditionally null allele of TRF2 resulted in substantial loss of 
TIN2 from telomeres, the formation of telomere dysfunction induced foci 
(TIFs), and the appearance of multiple telomeric signals and telomere loss at 
chromatid ends. We show that the ATM signaling pathway is activated in 
response to the telomere dysfunction induced by loss of TIN2 from the 
TRF2 complex, suggesting that TIN2 assists TRF2 in suppressing ATM 
activation at telomeres.  
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CHAPTER 1: INTRODUCTION  
Telomeric DNA 
 Telomeres are nucleoprotein complexes that cap the ends of linear 
chromosomes in eukaryotic cells. This DNA-protein complex allows cells to 
distinguish between natural chromosome ends and DNA breaks, preventing 
activation of DNA damage signals and repair pathways and permitting stable 
replication of chromosome ends.   
 The DNA component of telomeres is composed of GC-rich repeats 
that can vary in composition and length depending on the organism. In 
vertebrates, telomeres are comprised of 5’-TTAGGG-3’ tandem repeats that 
range in size from 2-20 kb for humans(25, 30, 85) (Fig. 1-1), 50-150 kb for 
laboratory mice(63), and 12-23 kb for canines(90). 
 The telomere terminus is not blunt-ended; instead, the 3’ end extends 
a G-rich single-stranded overhang, commonly referred to as the 3’ overhang 
or G-overhang(79, 82) (Fig. 1-1). It is likely that the G-overhang is a product of 
C-strand degradation by a nuclease(79). In humans, the C-strand 
preferentially ends with the sequence 3’-CCAATC-5’, suggesting that 
processing of the C strand terminus is tightly regulated. Conversely, the last 
base of the 3’ overhang shows much variation(103) (Fig. 1-1). 
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 The G-overhang is thought to invade the duplex telomeric DNA 
forming a lariat-like structure termed the t-loop(42) (Fig. 1-1). At the invasion 
site, the overhang base pairs with the C-strand, displacing the G-strand and 
forming a displacement loop (D loop). It is possible that recruitment of 
homologous recombination factors to telomeres is responsible for generating 
t-loops(122). Using electron microscopy, t-loops have been visualized at the 
telomeres of various organisms including vertebrates, worms, plants, 
trypanosomes, and ciliates(12, 42, 86, 88, 95). This conserved structure is proposed 
to play a role in telomere protection and length regulation.   
 
 
Figure 1-1. The structure of human telomeres.  
(A) Human chromosomes end in an array of TTAGGG repeats that varies in length. 
Proximal to the telomeric repeats is a segment of degenerate repeats and subtelomeric 
repetitive elements. The telomere terminus contains a long G-strand overhang. The 3’ end 
is not precisely defined whereas the 5’ end of human chromosomes nearly always 
features the sequence ATC-5’. (B) Schematic of the t-loop structure. The size of the loop 
is variable.  
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Telomere Maintenance by Telomerase 
 With each successive cell division, human primary cells suffer a loss 
of telomeric DNA. A small percentage of this loss is attributable to the “end 
replication problem”(92, 128). Initiation of DNA synthesis requires an RNA 
primer, which is later degraded and filled in by DNA polymerase. However, 
lack of 3’-5’ polymerization activity prevents DNA polymerase from 
extending the very end of the lagging strand left by the last RNA primer. 
This gap left by the RNA primer results in loss of telomeric DNA at a rate of 
about 3 bp/end/cell division. However, the shortening rate of human 
telomeres is actually around 50-200 bp/end/cell division(52). Nuclease attack 
of chromosome ends is likely responsible for such an increased rate of 
telomere loss. 
 To counteract telomere attrition, chromosome ends are maintained 
primarily by the enzyme telomerase(40, 41). Composed of a telomere-specific 
reverse transcriptase (TERT) and an RNA subunit (TERC), telomerase uses 
the 3’ end of the chromosome as a primer for reverse transcription of a short 
template sequence near the 5’ end of its RNA(37, 40, 41, 72, 89).  The RNA 
template is transcribed repeatedly, generating a tandem array of G-rich 
repeats. Telomere length maintenance is highly regulated at the level of 
telomerase expression(8).  
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 Catalytically active human telomerase consists of hTERT, hTERC, 
and the RNA-binding protein dyskerin(18). Mutations in hTERT, the RNA 
component of telomerase, dyskerin, or NOP10, a component of H/ACA 
snoRNP complexes, are associated with the human disease dyskeratosis 
congenita (DC)(83, 124, 125, 132). Patients with DC have severe bone marrow 
failure in addition to abnormal skin pigmentation, leukoplakia, and nail 
dystophy. Affected individuals also exhibit chromosome instability and a 
predisposition to develop certain types of malignancy(33, 83). These 
phenotypes are thought to result from the inability of telomerase to maintain 
the telomeres in stem cell compartments(83). 
 With the exception of germ line and stem cells, most adult human 
cells do not express telomerase(60). The telomeres of these cells continue to 
shorten with each division, and eventually the cells enter an irreversible state 
of arrested growth called replicative senescence(44, 45). Limiting the 
proliferative potential of cells can be viewed as a tumor suppressor 
mechanism. However, in most tumor cells, this pathway is disabled by 
telomerase activation, allowing telomeres to be maintained at a length long 
enough for continued growth(60).  This same phenomenon is seen in cell 
culture, where expression of hTERT in telomerase-negative human primary 
fibroblasts leads to telomere elongation and cellular immortalization(8, 84).   
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The Shelterin Complex 
Chromosome ends are protected and regulated by shelterin, a complex 
of six proteins (TRF1, TRF2, TIN2, TPP1, POT1, and Rap1) found 
predominately at telomeres(29). TRF1 and TRF2 bind directly to double-
stranded TTAGGG repeats, serving as anchors for other proteins to be 
recruited to telomeres(5, 7, 9, 17, 122). Rap1 is a TRF2-interacting partner(70) 
while TIN2 binds both TRF1 and TRF2, stabilizing their association with 
chromosome ends(61, 134). TIN2 also binds TPP1(49, 74, 135), which, in turn, 
recruits POT1, the single-stranded telomeric DNA binding protein(4, 76). 
These six proteins can be found in a single complex or as separate TRF1 and 
TRF2/Rap1 subcomplexes each linked to TIN2-TPP1-POT1(73, 134).  
 
Figure 2-2. The shelterin complex.  
The domain structures and interactions among the six components of human shelterin. 
Domains whose structures have been determined are shown. See text for references. 
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TRF1 and TRF2 
 TRF1 was the first human telomeric protein to be discovered, based 
on its ability to bind telomeric DNA(17). TRF2 was identified through 
database searches as a TRF-like protein(7, 9). The TRF proteins share a 
similar domain structure except at the N-terminus; TRF1 has an acidic 
domain, while TRF2 has a basic domain. Adjacent to the N-terminus is the 
TRF homology (TRFH) domain, which mediates homodimerization of the 
TRF proteins as well as interactions with binding partners. The three-
dimensional structures of the TRFH domains of TRF1 and TRF2 are almost 
identical, yet heterodimerization does not occur due to steric constraints(36). 
TRF1 and TRF2 bind double stranded TTAGGG repeats as homodimers 
using a conserved Myb domain in their C-terminus. The TRFH and Myb 
domain is connected by a flexible hinge domain, which allows the two Myb 
domains of a TRF1 dimer to bind DNA with little constraint on distance or 
orientation(5, 6).   
 TRF1 and TRF2 are both implicated in telomere length regulation, 
although the main function of TRF2 is to protect telomeres from being 
recognized as sites of DNA damage (discussed in detail below). 
Overexpression of TRF1 in the fibrosarcoma cell line HT1080 leads to a 
gradual and progressive shortening of telomeres, while a dominant-negative 
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mutant allele of TRF1, which lacks the DNA-binding Myb domain, induces 
telomere elongation(111, 121). Dissection of these phenotypes led to the 
conclusion that TRF1 acts as a negative regulator of telomere length in 
telomerase-positive cells. Overexpression of TRF2 in the same cell line 
leads to an initial telomere shortening phenotype, implying TRF2 is also a 
negative regulator of telomere length(111). Additionally, overexpression of 
TRF2 in telomerase-inhibited cells increases the rate of telomere 
shortening(1, 58).  
Rap1 
 Human Rap1 was identified in a yeast two-hybrid screen using TRF2 
as bait(70). This TRF2-interacting protein is comprised of three 
distinguishable domains including an N-terminal BRCT domain, a central 
Myb domain, and an acidic RCT domain (Rap1 C-terminus) that mediates 
the interaction with a small motif in the hinge domain of TRF2. Despite 
having a Myb domain, Rap1 does not bind TTAGGG repeats, but instead is 
recruited to telomeres through its association with TRF2(70). Rap1 is 
removed from telomeres and destabilized upon deletion of TRF2(10, 70). 
Overexpression studies indicate that Rap1 is a negative regulator of telomere 
length and also imply that the BRCT domain of Rap1 influences telomere  
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length homogeneity(69). Rap1 is an essential gene in mice, suggesting a 
possible role in telomere protection (van Overbeek and de Lange, 
unpublished). 
TIN2 
 TIN2 was originally identified as a TRF1-interacting protein in a yeast 
two-hybrid screen(62). It is now known that TIN2 interacts with both TRF1 
and TRF2(49, 61, 134). Crystallography studies reveal that TIN2 binds the 
TRFH domain of TRF1 using a small C-terminal peptide that contains a 
conserved F-X-L-X-P TRFH-docking motif (15). TRF2 association is 
mediated through the N-terminus of TIN2 and a small sequence in the hinge 
domain of TRF2(15). TIN2 can bind TRF1 and TRF2 independently or 
simultaneously, stabilizing the association of shelterin with telomeric DNA. 
Disruption of TIN2 by RNAi or mutation results in a DNA damage response 
at telomeres(61, 134). Similar studies also suggest that TIN2 is a negative 
regulator of telomere length(62, 133). TIN2 exerts its control over telomere 
length by protecting TRF1 from poly(ADP-ribosyl)ation (PARsylation) by 
the telomeric poly(ADP-ribose) polymerase (PARP), tankyrase1, and 
contributing to the accumulation of the TRF1 complex on telomeres(133). 
TIN2 also recruits POT1 to telomeres, which, as discussed below, acts at the 
telomere terminus to inhibit telomerase(59, 74, 76, 135).  
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 In addition to binding to TRF1 and TRF2, TIN2 interacts with a third 
partner, TPP1. TPP1 was discovered in biochemical experiments that sought 
TIN2 and POT1 interacting factors(49, 61, 74, 135). The N-terminus of TIN2 
localizes TPP1 to telomeres, which in turn, recruits POT1 to chromosome 
ends. Hence, TIN2 is the linchpin of shelterin, mediating interactions 
between double- and single-stranded telomeric DNA-binding proteins. 
TPP1/POT1 
 TPP1 uses its C-terminus to bind TIN2 and a centrally located domain 
to interact with POT1(74, 135). POT1 associates with TPP1 through its C-
terminus and contains two oligonucleotide/ oligosaccharide-binding (OB) 
folds that are highly specific for single-stranded telomeric DNA at its N-
terminus(4, 76, 77). The majority of POT1 is recruited to telomeres through the 
TPP1/TIN2 link to TRF1 and TRF2, and not through its ability to bind 
DNA(47, 74, 130, 135). Data from several different experiments support this 
claim. The deletion of the first OB fold of POT1 (POT1ΔOB) inhibits it from 
binding DNA, but does not prevent the recruitment of POT1 to telomeres(76). 
Furthermore, ChIP data suggests that longer telomeres recruit more POT1, 
even though the single-stranded DNA remains unaltered(76). Additionally,  
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depletion of TPP1 or expression of TPP1 mutants deficient in POT1 binding 
leads to removal of all detectable POT1 from telomeres. Finally, human 
POT1 is only recruited to telomeres when TPP1 is present(47, 74, 130).  
 POT1 has been implicated in both telomere length regulation as well 
as telomere protection. Overexpression of a mutant form of POT1 that lacks 
the DNA-binding domain, POT1ΔOB, or shRNA-mediated reduction in POT1 
protein levels abrogates TRF1-mediated control of telomere length and 
induces significant telomere elongation, suggesting that POT1 is a negative 
regulator of telomerase(74, 76, 135). This is supported by in vitro experiments 
showing POT1, but not POT1ΔOB, has the ability to inhibit telomerase 
activity(59). The protective function of POT1 was revealed by loss of POT1 
studies in human and mouse cells. Cells depleted of POT1 experience a 
DNA damage response and a telomere length phenotype(46, 48, 129). Not 
surprisingly, disruption of TPP1 function results in the same loss-of-POT1 
phenotypes(74, 130, 135).  
Shelterin Accessory Factors 
 Shelterin does not act alone to carry out the functions of telomeres; 
instead, a number of other proteins are recruited to chromosomes ends to 
assist in telomere maintenance. Most of these factors have roles independent 
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of telomere biology and only transiently associate with telomeres. In fact, 
the majority of these shelterin-associated proteins are DNA damage 
signaling and repair molecules. 
TRF1-associated factors 
 The acidic N-terminus of TRF1 binds to tankyrase1 and 2, poly(ADP-
ribose) polymerases that can modify TRF1. ADP-ribosylation of TRF1 
impedes its DNA binding activity in vitro, and tankyrase overexpression 
removes TRF1 from telomeres and promotes its degradation(21, 54, 97, 98, 108). 
TRF1 may also negatively regulate telomere length through its interaction 
with PINX1, a protein that can inhibit telomerase in vitro(136). Additionally, 
TRF1 has been shown to bind Ku(51), the BLM RecQ helicase(71, 93), and the 
ATM kinase(64). 
TRF2-associated factors 
 The TRF2-Rap1 complex interacts with a number of DNA 
damage/repair proteins. Pulldown experiments coupled to mass spectrometry 
analysis revealed that TRF2 associates with the Mre11-Rad50-Nbs1 
complex and the ERCC1/XPF nucleotide excision repair endonuclease(137, 
138). The Mre11 complex is thought to be involved in the repair of double-
strand breaks through homologous recombination, although its role at 
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telomeres has not been elucidated(118, 131), while ERCC1/XPF is required for 
removal of the 3’ overhang at deprotected telomeres(138). TRF2 also 
associates with the NHEJ factors DNA-PKcs and Ku70/80(26, 50, 91, 112). Ku 
acts to stimulate fusion of dysfunctional telomeres, yet protects chromosome 
ends from homologous recombination(11). The WRN and BLM helicases are 
associated with chromosome ends as well, where WRN is required for 
efficient lagging strand replication of telomeres(23, 71, 78, 93). Apollo, a putative 
5’ exonuclease, is also recruited to telomeres through its association with  
TRF2, where it protects telomeres in S phase(68, 120). Finally, the interaction 
of TRF2 with the ATM kinase is implicated in suppressing ATM activation 
at telomeres(56). 
Telomere Protection by TRF2 
TRF2 prevents activation of a DNA damage response at telomeres 
 Removal of TRF2 from telomeres, either by expression of a dominant 
negative allele of TRF2 in human cells or by genetic deletion in the mouse 
leads to an ATM-dependent DNA damage response(10, 55, 66, 122). The ATM 
kinase is activated by autophosphorylation on S1981, and Chk2, a 
downstream target of ATM is phosphorylated(10, 66, 117). Additionally, many 
of the same factors that localize to double-strand breaks are recruited to 
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TRF2-deficient telomeres. Proteins such as 53BP1, phosphorylated histone 
H2AX (γ-H2AX), ATM phosphorylated on S1981, Mre11, Nbs1, and 
MDC1 colocalize with telomeric DNA forming telomere dysfunction 
induced foci, or TIFs(27, 117). Loss of TRF2 also leads to senescence-like 
arrest or apoptosis, depending on the cell type(55, 122). The senescence 
associated with TRF2 deficiency resembles that of replicative senescence. 
Both lead to the stabilization of p53, induction of p21 and p16, 
hypophosphorylation of Rb, and positive staining for SA-β-galactosidase(109, 
117, 122). How TRF2 inhibits ATM from activating a DNA damage response at 
telomeres remains to be determined, but several models will be discussed in 
chapter four of this thesis.  
TRF2 inhibits non-homologous end joining at telomeres  
 Another consequence of TRF2 inhibition is the formation of telomere 
end-to-end fusions(10, 122). These fusion events are ATM-dependent and do 
not occur in the absence of DNA Ligase IV or Ku, indicating that they are 
generated by the NHEJ pathway(10, 11, 66, 110). A prerequisite to the fusion 
event is cleavage of the 3’ single-stranded overhang by the ERCC1/XPF 
nuclease(138). In mouse cells, overhang cleavage and end-joining are coupled, 
while in human cells the two processes occur independently(10, 32). 
13 
 Inhibition of TRF2 using a temperature-sensitive allele of TRF2 
(TRF2ts) gives further insight into the NHEJ process at telomeres(65). The 
inactivation of TRF2ts at 37ºC is rapid and reversible, permitting induction 
of short periods (3-6 hours) of telomere dysfunction in the G0, G1, and S/G2 
phases of the cell cycle. This has shown that NHEJ occurs primarily in G1, 
explaining the predominance of chromosome-type fusions and lack of sister 
fusions, which generally occur after replication in G2. Furthermore, it has 
been shown that NHEJ is repressed in S/G2 in a CDK-dependent manner(65).  
 TRF2 has been proposed to inhibit NHEJ at telomeres by mediating 
the formation of t-loops. The structure of the t-loop may execute this 
function by protecting the overhang from degradation as well as preventing 
the Ku70/80 complex, which requires a free double-stranded DNA end, from 
loading onto the telomere(11). Alternatively, just the presence of TRF2/Rap1 
at the telomere end may be enough to block NHEJ. This is supported by in 
vitro data showing that Rap1 could prevent end-joining of short telomere 
arrays(2).    
TRF2 prevents homologous recombination at telomeres 
 As described above, Ku is required to fuse telomeres by the NHEJ 
pathway in TRF2-inhibited cells. However, this is not the only telomeric 
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function attributed to Ku. In parallel with TRF2, Ku acts to prevent 
homologous recombination (HR) between telomeres on sister chromatids 
(telomere-sister chromatid exchange, T-SCE)(11). Loss of Ku alone did not 
cause significant changes in the structure of the telomeric DNA or activate a 
DNA damage response at telomeres. Only when both TRF2 and Ku are 
deleted is there an increase in the number of T-SCEs(11). This process can 
shorten and elongate individual telomeres when the exchanged segments are 
not equal, perhaps generating critically short telomeres that can threaten the 
viability of the cell.    
 Experiments using a mutant allele of TRF2 that lacks the basic 
domain, TRF2ΔB, also implicate TRF2 in protecting telomeres from 
inappropriate HR(127). Expression of TRF2ΔB leads to the induction of TIFs 
and the onset of senescence, but does not cause telomere fusions. Instead, 
TRF2ΔB cells experience telomere shortening and the formation of t-loop 
sized extrachromosomal telomeric circles, suggesting t-loop HR(127). T-loop 
HR requires formation of a Holliday junction (HJ), which is then resolved by 
a resolvase. The finding that t-loop HR is dependent on XRCC3, a proposed 
HJ resolvase, is consistent with this model(20, 75, 127).    
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Telomere Protection by POT1 
 Loss of POT1 by RNAi in human cells and by genetic deletion in the 
mouse has shown that POT1 functions in telomere protection. In human 
cells, POT1 deficiency leads to a transient DNA damage response in G1, 
causing the formation of TIFs and a reduction in the 3’ overhang(48). Mouse 
cells require two POT1 proteins, POT1a and POT1b, to protect telomeres. 
Deletion of POT1a results in a more severe telomere deprotection 
phenotype, while POT1b is mainly responsible for regulating exonucleolytic 
degradation of the C-rich telomere strand(46).  
 While TRF2 safeguards telomeres by inhibition of the ATM kinase, 
POT1 does so by repression of the ATR kinase(66). It is speculated that POT1 
competes with RPA for binding to single-stranded telomeric DNA, thus 
preventing the recruitment and activation of ATR.  
Telomere Length Regulation 
 In telomerase-expressing cells, the average length of telomeres is kept 
within a narrow species-specific range by maintaining a balance between 
telomerase-mediated elongation and the processes that lead to telomere 
shortening. Several experiments have shown that telomere length is 
regulated in cis at each individual chromosome end(1, 3, 43, 104, 113, 114). As such, 
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cis-acting length control cannot be exerted through changes in the 
expression of telomerase. Instead, shelterin modulates how telomerase acts 
at the telomere terminus through a negative feedback loop.  
 The mechanism by which shelterin exerts its negative effect on 
telomerase-mediated telomere elongation can be explained using a protein-
counting model(80, 121). In this model the accumulation of shelterin on the 
telomere depends on its length. Shorter telomeres can accept less negative 
regulators of telomere length, and as a consequence, the telomere has a 
greater chance of being elongated by telomerase. The telomere will continue 
to lengthen until it has become long enough to recruit sufficient amounts of 
shelterin to inhibit telomerase. The length of a telomere is therefore 
measured based on the amount of bound inhibitor.  Support for this model is 
provided by numerous telomere length regulation studies in human cells. 
Overexpression of TRF1 leads to the gradual and progressive shortening of 
telomeres, while a dominant negative allele of TRF1, which removes 
endogenous TRF1 from telomeres, causes telomere elongation(121). 
Similarly, disruption of TRF2, TIN2, TPP1, or POT1 by RNAi or by 
expression of mutant alleles results in telomere elongation, defining these 
proteins as negative regulators of telomere length (Takai, K and de Lange, 
unpublished)(62, 74, 133, 135). 
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 The shelterin-mediated negative regulation of telomerase must be 
relayed from the double-stranded telomeric DNA to the 3’ single-stranded 
overhang where POT1 has the potential to block telomerase. Evidence that 
POT1 is the terminal transducer of this inhibitory signal comes from 
experiments using POT1ΔOB. This mutant allele of POT1 fails to bind the 
telomere terminus and causes rapid and extensive telomere elongation(76). 
Additionally, direct competition between POT1 and telomerase for the 3’ 
single-stranded overhang was observed in vitro(59, 67). These findings suggest 
a model to explain how the signal is transduced from duplex DNA to the end 
of the telomere. As a telomere gets longer, more shelterin molecules are 
loaded onto double-stranded TTAGGG repeats, increasing the amount of 
TIN2/TPP1 recruited to the telomere. Since the majority of POT1 is 
localized to telomeres through its association with TIN2/TPP1(47, 74, 130), the 
possibility that POT1 will bind the telomere terminus and inhibit telomerase 
are substantially raised(24, 59).  
 Although most studies have focused on negative regulation of 
telomerase, not much is known about how telomerase is actually recruited to 
telomere ends. The fact that there are only 20-50 molecules of telomerase 
per cell raises the question of how such a small number of molecules can 
find its low abundant substrate(18). Recent data indicates that the TPP1/POT1 
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complex may contribute to recruiting telomerase. In fact, TPP1 has a direct 
interaction with telomerase and has been shown to increase the activity and 
processivity of the enzyme when complexed with POT1(126, 130). This posits 
TPP1/POT1 as both negative and positive regulators of the telomerase 
pathway(126, 130).  
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CHAPTER 2: TANKYRASE1 IS AN UPSTREAM NEGATIVE 
REGULATOR OF TRF1 AND A POSITIVE REGULATOR OF 
TELOMERE LENGTH 
Introduction 
 Telomeres can be elongated by the telomere specific reverse 
transcriptase telomerase and shortened through the effects of DNA 
replication and nucleolytic attack(40, 41, 92, 128). The TTAGGG repeat array of 
vertebrate telomeres has a species-specific length setting, suggesting that 
these forces are balanced in the germ line(22). Telomere length control has 
been primarily studied in human tumor cells that express telomerase. Such 
cells often maintain the length of their telomeres within a set range. This 
telomere length homeostasis is achieved through a negative feedback loop 
involving shelterin, the telomere-specific protein complex(29, 121). Shelterin is 
comprised of six proteins (TRF1, TRF2, POT1, TPP1, TIN2, and Rap1) 
whose abundance at chromosome ends is dictated by the length of the 
duplex telomeric repeat array(29). All shelterin components behave as 
negative regulators of telomere elongation by telomerase. Inhibition of 
TRF1, TPP1, TIN2, and POT1 results in telomere elongation whereas 
overexpression of several shelterin components shortens the length of the 
20 
telomeres(72, 121, 133, 134). Telomere healing experiments demonstrated that 
cells have the ability to monitor and regulate telomerase at individual 
telomeres, and tethering of TRF1 at subtelomeric sites showed that TRF1 
can modulate telomere length in cis(1, 3, 43, 104, 113, 114). These findings have 
resulted in a model for shelterin dependent telomere length homeostasis 
whereby long telomeres contain more shelterin and thus have a diminished 
chance of being elongated further by telomerase(80, 121). A key player in this 
negative feedback loop is POT1, whose binding to the single-stranded 
telomeric DNA appears to block telomerase in vivo(72, 76, 135) and in vitro(59, 67, 
126, 130).  
The length of human telomeres can be reset by manipulating 
tankyrase1, a TRF1-associated poly(ADP-ribose) polymerase (PARP). 
Tankyrase1 (TRF1-interacting, ankyrin-related ADP-ribose polymerase) 
consists of four domains:  an N-terminal His, Pro, Ser (HPS) rich region, a 
central ankyrin domain containing 24 ankyrin repeats, a region homologous 
to the sterile alpha module (SAM) motif, and a C-terminal domain with 
homology to the catalytic domain of PARPs(108). The ankyrin domain of 
tankyrase1 is composed of five conserved subdomains, which all serve as 
binding sites for TRF1(31, 101, 102). TRF1 interacts with tankyrase1 using a 
conserved motif its N-terminal acidic domain(97). Tankyrase1 lacks a nuclear 
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localization signal and is only found at telomeres through its association 
with TRF1(108). In addition to telomeres, tankyrase1 associates with a diverse 
set of proteins in different subcellular compartments(16, 106). 
Tankyrase1 is a fully functional PARP, capable of poly(ADP-
ribosyl)ating (PARsylating) itself and TRF1. Using nicotinamide adenine 
dinucleotide (NAD+) as a substrate, tankyrase1 catalyzes the formation of 
poly(ADP-ribose) (PAR) onto its protein acceptors(108). In vitro, tankyrase1-
mediated modification of TRF1 causes a decrease in the DNA binding 
affinity of TRF1, while in vivo targeting of tankyrase1 to the nucleus 
promotes TRF1 delocalization from telomeres and degradation by ubiquitin-
mediated proteolysis(14, 108). Furthermore, overexpression of nuclear 
tankyrase1 leads to a telomere elongation phenotype that requires the 
catalytic activity of the PARP domain of tankyrase 1(21, 100, 107), although a 
recent report from the Seimiya group suggests otherwise(87). TRF1 can be 
protected from the effect of tankyrase1 by TIN2, which forms a ternary 
complex with tankyrase1 and TRF1 and blocks the PARsylation of TRF1 in 
vitro(133). When TIN2 is inhibited in vivo, TRF1 appears more sensitive to 
the endogenous tankyrase1 and telomere elongation occurs.  
 Collectively, these results implicate tankyrase1 as a positive regulator 
of telomere elongation by telomerase. Several approaches have been used to 
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provide further evidence for such a role of endogenous tankyrase1. PARP 
inhibitors were shown to induce telomere shortening, but it has been difficult 
to ascribe this phenotype to inhibition of tankyrase1 rather than one of the 
other PARPs(100). Dominant negative alleles of tankyrase1 have largely 
failed to yield the expected telomere shortening phenotypes(21, 107), although 
success with one allele has been reported(100). Here we investigate this issue 
further by examining the telomere dynamics of cells targeted with 
tankyrase1 shRNAs and through the use of a tankyrase1-resistant allele of 
TRF1. The following results were published by Donigian and de Lange in 
the Journal of Biological Chemistry(34). 
Results 
Tankyrase1 shRNAs affect telomerase-mediated telomere elongation 
 To further address the role of tankyrase1 as a positive regulator of 
telomere length, we examined the telomere length of cells treated with 
tankyrase1 shRNAs. Since tankyrase1 deficiency is known to induce a 
mitotic arrest(13, 35) and thus incompatible with long-term culturing, we 
aimed for shRNAs that would generate partial knockdown. We tested 
shRNAs for the residual tankyrase1 protein levels by quantitative western 
blotting (Fig. 2-1A, D) and identified two shRNAs that lowered the 
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tankyrase1 level about two-fold. A third shRNA had a very modest effect, 
and a fourth shRNA did not affect tankyrase1 and served as a control. None 
of these shRNAs affected the proliferation of the cells (Fig. 2-1B).  
 Since the knockdown of tankyrase1 is partial, we anticipated that its 
effect would be most easily monitored under conditions where telomerase is 
not in excess, since high levels of telomerase can mask regulatory 
pathways(24). Our BJ-hTERT cells showed gradual telomere shortening, 
despite the fact that they were expressing telomerase. Their shortening rate 
was 25-30 bp/end/population doubling (PD) which is significantly less than 
for telomerase negative BJ cells (80 bp/end/PD)(58), indicating that 
telomerase is active at a significant but low level. If tankyrase1 contributes 
to the telomerase pathway in these cells, we would expect to detect an 
increase in the shortening rate from 25-30 bp/end/PD to the maximal rate of 
80 bp/end/PD. In order to be able to determine such changes accurately, BJ-
hTERT cells expressing the various shRNAs were cultured in parallel with 
the vector control for approximately 130 PDs, and the telomere shortening 
rates were determined based on multiple genomic blots at various PDs (Fig. 
2-1C, D). The results indicated that tankyrase1 shRNAs sh1 and sh5 resulted 
in a significant increase in the shortening rate to 43±2.2 and 46±2.5 
bp/end/PD, respectively. The less effective sh3 had a minor effect 
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(shortening at 35±0.5 bp/end/PD) and as expected, cells expressing the 
ineffective sh4 had a similar shortening rate as the vector control cells 
(31±3.1 bp/end/PD). Together with previous data indicating that tankyrase1 
does not affect telomere dynamics in telomerase negative cells(21), our results 
confirm the role for tankyrase1 as a positive regulator of the telomerase 
pathway. 
Mutation of the tankyrase1 binding motif of TRF1 
 In the simplest model for the effect of tankyrase1 on telomere 
maintenance, the enzyme binds and PARsylates TRF1, removing TRF1 from 
telomeres. Here, tankyrase1 only acts upstream of TRF1 and is not required 
for the ability of TRF1 to function as a negative regulator of telomere length. 
However, the data do not exclude the possibility that tankyrase1 may also 
have a role downstream of TRF1, affecting the negative regulation of 
telomere length by TRF1(133). In order to examine this possibility, we 
generated a TRF1 mutant that lacks a functional tankyrase1 interaction motif 
and determined whether it was still capable of negatively regulating 
telomere length. In characterizing the minimal tankyrase-binding motif, it 
was shown that the first residue in the hexapeptide RXXADG is critical for 
tankyrase-binding, while substitution of the second residue had no effect on 
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binding(97). Using site-directed mutagenesis, a mutation was made in the N-
terminal 13RGCADG18 motif of hTRF1 by converting arginine 13 to an 
 
Figure 2-1. Tankyrase1 suppression causes telomere shortening.  
(A) Western blots showing tankyrase1 protein levels in BJ-hTERT cells expressing 
shRNA-encoding retroviruses and the vector control. Total cellular proteins were 
analyzed by immunoblotting using antibodies to tankyrase1 (465) and to γ-tubulin. (B) 
Graph of growth curves of BJ-hTERT cells infected with tankyrase1 shRNAs and the 
vector control. Cells were selected with puromycin for 5 days and then proliferation was 
monitored over several months. (C) Genomic blot of telomeric restriction fragments in 
four BJ-hTERT cell lines infected with the indicated tankyrase1 shRNA retroviruses and 
the vector control. DNA agarose plugs were prepared at ~PD 130, digested with AluI and 
MboI, and analyzed by Southern blotting using a double-stranded TTAGGG repeat 
probe. (D) Table summarizing the relative tankyrase1 protein levels and the telomere 
shortening rates of BJ-hTERT cells expressing tankyrase1 shRNAs. 
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alanine (Fig. 2-2A). Additionally, glycine 14 was inadvertently mutated to 
an arginine. The ability of this hTRF1ΔTank allele to bind tankyrase1 was 
tested by far western assay. Baculovirus-derived TIN2, tankyrase1, and 
Rap1 (as a negative control) were probed with in vitro translated 35S-labeled 
hTRF1 and hTRF1ΔTank. The results showed that wild type hTRF1 was able 
to bind tankyrase1 while hTRF1ΔTank failed to do so. On the other hand, the 
mutation did not affect the TRF1-TIN2 association, as demonstrated by the 
robust signal in the TIN2 lane for both wild type hTRF1 and the mutant (Fig 
2-2B). Co-immunoprecipitation experiments also indicated that hTRF1ΔTank 
no longer bound tankyrase1. MYC-tagged hTRF1 and hTRF1ΔTank were 
transiently co-transfected with FLAG-NLS-tagged tankyrase1 (FN-
tankyrase1) into 293T cells, and TRF1 was precipitated from the cells using 
an antibody against MYC. The immunoblot shows that wild type hTRF1 
was able to pull down tankyrase1 while hTRF1ΔTank failed to do so (Fig. 2-
2C).  
hTRF1ΔTank is resistant to tankyrase1 activity in vitro and in vivo  
 We next tested whether the hTRF1ΔTank mutant could be PARsylated 
by tankyrase1 in an in vitro PARP assay (Fig. 2-3). The PARsylation of  
hTRF1ΔTank by tankyrase1 was reduced by 4-5-fold compared to wild type 
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Figure 2-2. hTRF1ΔTank and mTRF1 do not bind tankyrase1.  
(A) Alignment of the N-terminal acidic domain of hTRF1, hTRF1ΔTank, and mTRF1. The 
TRF1 tankyrase1-binding consensus sequence is also shown. (B) Far-western analysis of 
the tankyrase1-binding ability of hTRF1, hTRF1ΔTank, and mTRF1. Each lane contains 2 
μg of purified recombinant protein derived from insect cells using a His-tag. The proteins 
were subjected to SDS-PAGE, blotted onto nitrocellulose, and incubated with the 
indicated 35S-labeled IVT protein. (C) Co-immunoprecipitations from transfected 293T 
cells. MYC-tagged hTRF1, hTRF1ΔTank, mTRF1 and FN-tankyrase1 were transiently 
transfected into 293T cells in the combinations shown. Whole-cell extracts (input) were 
immunoprecipitated (IP) using an antibody to MYC (9E10). A small fraction of FN-
tankyrase1 is recovered non-specifically in the IPs resulting in the band indicated with an 
asterisk.   
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hTRF1 (22±7.6% of wild type in 3 experiments). The discrepancy between 
the ability of hTRF1ΔTank to bind tankyrase1 and to be modified by 
tankyrase1 may lie in the sensitivity of the assays used. It is possible that 
hTRF1ΔTank can still loosely associate with tankyrase1 outside of its acidic 
domain(101), allowing for modest PARsylation of hTRF1ΔTank. In fact, this is 
the case with chicken TRF1, which binds tankyrase1 even though it lacks the 
RXXADG tankyrase-binding motif(31).  
 
 
Figure 2-3. hTRF1ΔTank and mTRF1 are not readily PARsylated by tankyrase1.  
The autoradiograph (left) and Coomassie blue-stained gel (right) from a tankyrase1 
PARP assay. Each lane contains 4 μg of the indicated proteins derived from insect cells 
or E. coli cells (GST-mTRF1) in a reaction with 32P-β-NAD+. Products from each 
reaction were subjected to SDS-PAGE and processed for autoradiography or Coomassie 
blue staining. The blot shown here yielded a hTRF1ΔTank signal that was 12% of the band 
intensity of wild type hTRF1. 
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 Finally, we tested the ability of hTRF1ΔTank to resist removal from the 
telomere in the presence of excess nuclear tankyrase1 in vivo. HeLa cells 
expressing MYC-tagged hTRF1 or hTRF1ΔTank were transiently transfected 
with FN-tankyrase1, and the removal of TRF1 was monitored by indirect 
immunofluorescence. As expected, hTRF1 was no longer detectable at 
telomeres in the nuclei that expressed tankyrase1 (Fig. 2-4A). In contrast,  
hTRF1ΔTank retained its punctuate pattern in tankyrase1-expressing cells (Fig. 
2-4B). We conclude that hTRF1ΔTank has largely lost tankyrase1 interaction 
in vitro and in vivo.  
hTRF1ΔTank behaves as a negative regulator of telomere length 
 In order to evaluate the effect of the diminished tankyrase1 interaction 
on the telomere length regulatory activity of TRF1, we analyzed telomere 
length in BJ-hTERT and HTC75 cells overexpressing wild type hTRF1 and 
hTRF1ΔTank. Both proteins were expressed at the same level (Fig. 2-5A). 
Their overexpression was such that only ~15% of the total TRF1 in the cells 
was derived from the endogenous (wild type) locus. The TRF1 mutant allele 
had no effect on the viability of the cells, and they proliferated at the same 
rate as cells expressing hTRF1 or the vector control (Fig. 2-5B and data not 
shown). As seen in the tankyrase1 shRNA experiment, the BJ-hTERT vector  
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 Figure 2-4. Overexpression of tankyrase1 in the nucleus releases hTRF1, but not 
hTRF1ΔTank, mTRF1, or other mouse shelterin proteins.  
Indirect immunofluorescence of TRF1 localization in (A-C) HeLa1.2.11 cells stably 
expressing (A) MYC-hTRF1, (B) MYC-hTRF1ΔTank or (C) MYC-mTRF1, or in (D) 
mouse NIH 3T3 cells transiently transfected with FN-tankyrase1 or mock transfected. (E-
I) Indirect immunofluorescence of mouse shelterin proteins (E) mTRF1, (F) mTIN2, (G) 
mRap1, (H) mPOT1a, and (I) mPOT1b in immortalized MEFs transiently transfected 
with FN-tankyrase1. For H and I, immortalized MEFs stably expressing MYC-mPOT1a 
and MYC-mPOT1b were used, respectively.  
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control cells experienced mild telomere shortening (21±9.5 bp/end/PD) 
while the HTC75 vector control cells remained at a stable telomere length 
setting. Overexpression of hTRF1 led to telomere shortening at a rate of 
66±3.5 bp/end/PD in BJ-hTERT cells and 11±1.0 bp/end/PD in HTC75 cells 
(Fig. 2-5C, D; data not shown). A similar shortening phenotype was evident 
for the cells expressing hTRF1ΔTank, which induced a shortening rate of 
68±7.0 bp/end/PD in BJ-hTERT cells and 12±0.5 bp/end/PD in HTC75 cells 
(Fig. 2-5C, D; data not shown). This result implies that diminished 
recruitment of tankyrase1 does not have a strong impact on the ability of 
TRF1 to negatively regulate telomere length. Thus, tankyrase1 appears to 
primarily act upstream of TRF1 in the telomere length regulation pathway.  
Mouse TRF1 does not interact with tankyrase1 in vitro and in vivo  
 Interestingly, the N-terminus of mouse TRF1 lacks the RGCADG 
motif (Fig. 2-2A), and does not bind tankyrase1(97). This would suggest that 
the wild type mTRF1 would resemble the hTRF1ΔTank mutant. To test this 
idea, we asked whether full-length mTRF1 could interact with and be 
modified by tankyrase1. Human and mouse tankyrase1 are 98% identical 
overall with most differences occurring in the N-terminus, which is not 
implicated in the interaction with TRF1 or its PARP activity. We therefore  
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Figure 2-5. Overexpression of hTRF1ΔTank causes telomere shortening.  
(A) Western blots of endogenous TRF1 and exogenously expressed MYC-tagged hTRF1 
and hTRF1ΔTank in BJ-hTERT cells. Total cellular proteins were analyzed by 
immunoblotting using antibodies to TRF1 (371), MYC (9E10), and γ-tubulin. (B) Graph 
of growth curves of BJ-hTERT cells infected with hTRF1, hTRF1ΔTank, and the vector 
control. Cells were selected with puromycin for 5 days and then proliferation was 
monitored over 100 PDs. (C) Genomic blot of telomeric restriction fragments in BJ-
hTERT cell lines infected with hTRF1 and hTRF1ΔTank retroviruses and the vector 
control. DNA agarose plugs were prepared at the indicated PDs, digested with AluI and 
MboI, and analyzed by Southern blotting using a double-stranded TTAGGG repeat 
probe. (D) Table summarizing the telomere shortening rates of BJ-hTERT and HTC75 
cells expressing hTRF1, hTRF1ΔTank, and the vector control. 
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used the available human tankyrase1 constructs for these tests because this 
approach allowed comparison of human and mouse TRF1 in the same 
experiment. In the far western assay, mTRF1 behaved similarly to 
hTRF1ΔTank, forming a complex with TIN2, yet failing to interact with 
tankyrase1 (Fig. 2-2B). Furthermore, mTRF1 did not bind tankyrase1 based 
on their lack of co-IP from transfected 293T cells (Fig. 2-2C). Additionally, 
GST-mTRF1 was not PARsylated by tankyrase1 in an in vitro PARP assay 
(Fig. 2-3). The reaction was validated by showing that hTRF1 and 
tankyrase1 were still modified in the presence of GST-mTRF1. This control 
was included to rule out that GST-mTRF1, the only protein prepared from 
bacteria, did not contain a fortuitous inhibitor of the PARP reaction. The 
effect of tankyrase1 on mTRF1 telomere localization was also examined. 
HeLa 1.2.11 cells infected with MYC-mTRF1 (Fig. 2-4C), NIH 3T3 cells 
(Fig. 2-4D), and MEFs (Fig. 2-4E) were transfected with FN-tankyrase1, 
and the distribution of mTRF1 was assessed by IF. As with hTRF1ΔTank, 
tankyrase1 failed to remove mTRF1 from telomeres. We also examined the 
effect of nuclear overexpression of tankyrase1 on the telomeric localization 
of other shelterin components, including mTIN2 (Fig. 2-4F), mRap1 (Fig. 2-
4G), mPOT1a (Fig. 2-4H), and mPOT1b (Fig. 2-4E). For none of these 
shelterin proteins was tankyrase1 found to affect their localization. 
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Discussion 
 Reduction of tankyrase1 protein levels by shRNA resulted in telomere 
shortening that was proportional to the level of knockdown while a 
tankyrase1-resistant form of TRF1 had no effect on the ability of TRF1 to 
regulate telomere length. These findings suggest that tankyrase1 is a positive 
regulator of telomere length and does not function downstream of TRF1. 
Furthermore, we showed that mouse TRF1 does not interact with 
tankyrase1, is not PARsylated by tankyrase1 in vitro, or is not removed from 
telomeres when tankyrase1 is overexpressed in mouse nuclei. Similarly, all 
mouse shelterin proteins were resistant to tankyrase1 overexpression and 
remained bound to telomeres. Consistent with these results, tankyrase1 
knockout mice do not have defects in telomere length maintenance (Chiang 
et al., unpublished).  
 Collectively, the data imply that tankyrase1 does not have the same 
role at mouse telomeres as it does at human telomeres. This is not the first 
time a difference has been observed between human and mouse telomeres. 
Recently, it was discovered that rodent shelterin is comprised of two 
functionally distinct POT1 proteins, both of which are required to protect 
telomeres, whereas human shelterin only includes a single POT1 protein(46). 
The use of tankyrase1 as a shelterin accessory factor is another example of 
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the rapid evolution of the telomere/telomerase system. Tankyrase1 
presumably provides an additional level of control over telomere elongation 
by telomerase. Perhaps the tankyrase1 pathway allows the subset of 
telomerase-positive human somatic cells to control the rate of telomere 
shortening. 
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CHAPTER 3: TIN2 PREFERENTIALLY BINDS THE TRFH 
DOMAIN OF TRF1 AND THE HINGE DOMAIN OF TRF2  
Introduction  
 The TTAGGG repeat arrays of mammalian telomeres associate with 
two related telomeric DNA-binding proteins, TRF1 and TRF2(7, 9, 17). These 
factors have closely related C-terminal Myb-type DNA binding domains and 
bind TTAGGG sequences as dimers or higher order oligomers. Dimerization 
is mediated by the TRF-homology (TRFH) domain, the signature motif of 
this family of telomeric proteins(5, 36). The crystal structure of the TRFH 
domains of TRF1 and TRF2 shows that the heterodimerization of TRF1 and 
TRF2 is impeded by crucial amino acid differences in the main dimerization 
interface(5, 36), and TRF1/TRF2 heterodimers are not formed in vitro or in 
vivo(9). Therefore, before this study, the prevailing view had been that TRF1 
and TRF2 form separate complexes at telomeres. 
 The two-complex model was reinforced by functional studies 
revealing distinct roles for TRF1 and TRF2 at telomeres. Originally, TRF1, 
TIN2, TPP1, and POT1 were mainly implicated in telomere-length 
homeostasis, a process that regulates the maintenance of telomeric DNA by 
telomerase(19, 62, 74, 76, 121, 133, 135). It was not until after this study that we 
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learned of the protective function of POT1/TPP1 in mammalian cells(46-48, 
129). On the other hand, TRF2 has always been associated with telomere 
protection. Its inhibition leads to dysfunctional telomeres that are detected 
and processed by the DNA damage response machinery(10, 27, 55, 117, 122). 
However, targeted deletion of TRF1 in mice results in early embryonic 
lethality, and ES cells deprived of TRF1 function die rapidly(53, 57). The cell-
lethal phenotype of TRF1 loss would not be expected if these proteins acted 
solely to regulate telomere length and suggests that TRF1 may be 
contributing to telomere protection. Interestingly, TRF1-deficient ES cells 
show diminished presence of TRF2 at chromosome ends(53), suggesting a 
link between these two complexes.  
 This chapter reveals that TIN2 is the connecting factor between the 
TRF1 and TRF2 complexes. We show that the C terminus of TIN2 binds the 
TRFH domain of TRF1, while the N terminus of TIN2 interacts with a small 
motif in the hinge domain of TRF2. This allows TIN2 to bind TRF1 and 
TRF2 independently or simultaneously, bridging the TPP1-POT1 complex 
not only to TRF1, but also to TRF2 and stabilizing shelterin proteins at 
telomeres.  
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Results 
Shelterin and its subcomplexes 
 Several experiments led to the conclusion that TRF1 and TRF2 exist 
in independent complexes as well as a comprehensive shelterin unit with all 
six components. One clue that there was a link between the TRF1 and TRF2 
complexes came from an experiment in which TRF1 was targeted by RNAi 
and analyzed by IF. Knockdown of TRF1 in HeLa cells resulted not only in 
loss of TRF1 from telomeres, but a reduction in the amount of TRF2 and 
Rap1 at chromosome ends(134). A possible explanation for the effect of TRF1 
siRNA on TRF2 is the presence of a proteinaceous link between these two 
complexes that stabilizes TRF2 on telomeres. To find TRF1- and TRF2-
interacting factors that might represent such a linking factor, my colleagues 
performed mass spectrometry on isolated TRF1 and TRF2 complexes from 
HeLaS3 cells. Found in association with the TRF2-associated protein, Rap1, 
were peptides derived from TRF1, PIP1, and POT1(134), and conversely, 
peptides derived from TRF2 and Rap1 were identified in the TRF1-TIN2 
complex(135). My own data were consistent with these findings. When 
FLAG-tagged TRF1 was overexpressed and precipitated from BJ-hTERT 
cells, TRF2 and Rap1 were pulled down as well (Fig. 3-1). Treatment of 
lysates with ethidium bromide or RNase A did not affect the recovery of 
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TRF2 and Rap1 in the TRF1/TIN2 IPs, suggesting that these proteins were 
not tethered by nucleic acids. The interaction between the TRF1 and TRF2 
complexes was, however, sensitive to high salt concentrations(134). This can 
explain why TRF1 and its associated factors were not recovered in a 
previously analyzed TRF2 complex that was isolated from a high salt 
heparin chromatography fraction(137, 138).   
 
Figure 3-1. Co-IP of the TRF1 and TRF2 complexes.  
Immunoblot of extracts from retrovirally infected BJ-hTERT cells expressing FLAG-
tagged TRF1 or vector alone immunoprecipitated with FLAG beads and eluted with 
FLAG peptide. Antibodies used: anti-FLAG, M2; anti-TIN2, 864; anti-TRF2, 647; and 
anti-Rap1, 765; control is a nonspecific band that reacted with the Rap1 antibody. 
 
 Gel filtration was used to gain further insight into the interaction 
between the TRF2 complex and the TRF1 complex. Endogenous telomeric 
protein complexes of HeLa cells were size-fractionated and constituent 
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proteins were identified by immunoblotting (Fig. 3-2; experiment done by 
Jeffrey Ye). A TRF2-Rap1 complex (complex III) was detected in the lower 
molecular mass range that appeared to lack the other telomeric proteins. This 
is consistent with the direct interaction between these two factors. The 
fractions in the 2 MDa range (the exclusion limit of the column) contained 
tankyrase 1, TRF1, TIN2, POT1, TRF2, and hRap1. Although the co-elution 
of these proteins could be due to the presence of a single large complex, it is 
also possible that these high molecular mass fractions contain multiple 
complexes that each have a molecular mass in the 2-MDa range or that they 
are held together by DNA. The most informative complex was recovered in 
fractions 24–26 (complex II), which contained TRF2, Rap1, TIN2, and 
POT1 but lacked TRF1 and tankyrase 1. The reduced presence of TRF1 in 
these fractions suggested that the association of TIN2 and POT1 with 
TRF2/Rap1 is not mediated by TRF1. The lack of requirement for TRF1 in 
this association further confirmed that DNA tethering is an unlikely source 
of the connection between the telomeric complexes and points to an 
association of either TIN2 or POT1 or one of their interacting partners with 
the TRF2-Rap1 complex. 
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Figure 3-2. Gel-filtration analysis of telomeric complexes.  
Immunoblotting analysis of endogenous telomeric proteins in HeLa nuclear extract 
fractionated on Sephacryl S-300. 10 µl of the indicated fractions were loaded per lane. 
Antibodies used: anti-tankyrase 1, number 465; anti-TRF1, 371; anti-TIN2, 864; anti-
POT1, 978; anti-TRF2, 647; and anti-Rap1, 765. Molecular mass markers used were blue 
dextran (2 MDa), thyroglobulin (669 kDa), and bovine serum albumin (67 kDa). (Figure 
done by Jeffrey Ye) 
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Direct Binding of TIN2 to TRF1 and TRF2 
 Because TIN2 appeared to be shared between the TRF1 and TRF2 
complexes, we tested its ability to interact with TRF2 and/or Rap1 by far 
western assaying. When purified baculovirus-derived telomeric proteins 
were probed with [35S]methionine-labeled in vitro translated (IVT) TIN2, a 
robust interaction of TIN2 with TRF2 was detected, and the basic domain of 
TRF2 was dispensable for this association (Fig. 3-3A). TIN2, however, 
failed to bind Rap1, POT1, TRF1, or itself. The fact that TIN2 did not 
interact with TRF1 was surprising, but it is possible that the denaturing 
conditions of the far western assay prevented filter-bound TRF1 from being 
a good substrate for TIN2 because the reverse reaction proved successful; 
native IVT TRF1 was able to interact with filter-bound TIN2. We next asked 
which region of TIN2 was responsible for binding TRF2. TIN2–13, a C-
terminal fragment of TIN2 that retains its TRF1 interacting domain, was 
used to probe blotted TRF2 with negative results (data not shown). These 
data corroborate the yeast two-hybrid data indicating that TIN2 interacts 
with TRF2 and that this interaction requires sequences present in the N 
terminus of TIN2(134). 
 Having established that TIN2 binds to TRF2 as well as to TRF1, we 
wanted to determine whether TIN2 can link TRF1 to TRF2. To address this 
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issue, we performed a modified Far-Western assay in which unlabeled TIN2 
was tested for its ability to mediate binding of labeled TRF1 to filter-bound 
TRF2 (Fig. 3-3B). As expected, in the absence of TIN2, IVT TRF1 
associated with filter-bound TIN2 but did not bind to TRF2. However, when 
the same assay with labeled TRF1 was performed in the presence of 
unlabeled TIN2 in a binding mixture, TRF1 had the ability to associate with 
TRF2. This result suggested that TIN2 can tether TRF1 to TRF2.  
 As discussed earlier, depletion of TRF1 from telomeres leads to 
partial removal of TRF2 as well. The finding that TIN2 can form a 
proteinaceous link between TRF1 and TRF2 suggested that TIN2 loss would 
also destabilize TRF2 at telomeres. To test this, siRNA depletion of TIN2 
was implemented. As previously shown, loss of TIN2 diminished the 
abundance of TRF1at telomeres, in part because of the tankyrase-mediated 
modification of TRF1(133). Along with TRF1, the telomeric accumulation of 
TRF2 and Rap1 was also strongly reduced by TIN2 knockdown(134). Thus, 
loss of TIN2 affects the presence of TRF2 at chromosome ends. 
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Figure 3-3. TIN2 interacts with TRF1 and TRF2 simultaneously.  
(A) Far-western analysis of indicated telomeric proteins with [35S]TIN2 IVT protein. 
Each lane contains 2 µg of purified protein derived from E. coli (using glutathione S-
transferase; POT1) or Sf21 cells (using a His-tag; all other proteins). The proteins were 
subjected to SDS-PAGE, stained with Coomassie Blue (left), or blotted onto 
nitrocellulose and incubated with [35S]TIN2 IVT protein (right). (B) Modified far-
western analysis of the ability of TIN2 to bridge TRF1 to TRF2. From left to right, 
Coomassie blue-stained gel loaded with 2 µg of purified baculovirus TRF2, TIN2, and 
Rap1; nitrocellulose blot of the same proteins preincubated with baculovirus TIN2 
followed by incubation with mock 35S-labeled IVT protein (no DNA was added to the 
IVT reaction); blot preincubated without protein followed by incubation with 35S-labeled 
TRF1 IVT protein; blot preincubated with baculovirus TIN2 followed by incubation with 
35S-labeled TRF1 IVT protein. 
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Mapping of the TRF2 TIN2-binding domain 
 Having shown that TIN2 can bind to both TRF1 and TRF2, we set out 
to create a separation-of-function mutant whereby we could examine the role 
of TIN2 when it is bound exclusively to TRF2. To do this, the region in 
TRF2 that associates with TIN2 needed to be determined. We once again 
used far westerns to map the TIN2-binding motif in TRF2. In these 
experiments, lysates from induced E. coli BL21 bacterial cultures that 
expressed various GST-fused TRF2 constructs were used as the filter-bound 
protein source while [35S]methionine-labeled IVT TIN2 was used as the 
probe(15). We first tested the known domains of TRF2 (Fig. 3-4A). TIN2 
failed to interact with the TRFH or Myb domains, but showed a strong 
interaction with full-length TRF2, TRF2ΔB, and, most informative, the hinge 
or linker region in TRF2 (Fig. 3-5B). The hinge domain was then broken 
down into smaller GST-fused constructs to narrow in on the area of 
interaction. TIN2 only bound to the GST fusion containing aa 352-406 of 
TRF2. Further analysis of this short amino acid stretch revealed that TIN2 
preferentially interacted with the N-terminal portion of this region from 
residue 352 to 385 (Fig. 3-5B). Finally, the minimal TRF2 TIN2-binding 
motif was mapped to aa 352-365 of the hinge domain. Deletion of this 
region from GST-TRF2 completely abrogated TIN2 binding in the far 
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western assay(15) (Fig. 3-5B). For cloning simplicity, the deletion was made 
from residues 352-367. TRF2Δ352-367 will be referred to as TRF2ΔT (for 
deletion of TIN2) from here on out.   
 The inability of TIN2 to bind TRF2ΔT was further verified by co-IP in 
293T cells(15). Myc-tagged TRF2WT and TRF2ΔT were co-transfected with 
FLAG-HA-tagged TIN2 into 293T cells, and TRF2 was precipitated from 
the cells 24 hours later using a Myc antibody. So as to not disrupt the salt 
sensitive TRF2-TIN2 interaction, the lysates were prepared under 
physiological salt conditions. The western blot reveals that TRF2WT was able 
to pull down TIN2, while very little TIN2 was associated with TRF2ΔT (Fig. 
3-5C). In fact, TRF2ΔT may dimerize with endogenous TRF2, and the small 
amount of TIN2 seen in the IP could be a result of its interaction with this 
population of TRF2. The decrease in the amount of TIN2 in the TRF2ΔT 
lysate compared to the wild type control suggests that the interaction 
between TRF2 and TIN2 improves the stability of TIN2. 
 Previous studies have shown that the TRF1-TIN2 interaction is 
mediated by the TRFH domain of TRF1 and the C terminus of TIN2(62). 
Considering that the TRFH domains of TRF1 and TRF2 have almost 
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identical three-dimensional structures(36), we were surprised that TIN2 did 
not associate with the TRFH domain of TRF2, but instead used its N 
terminus to bind the hinge region of TRF2. 
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Figure 3-4. TIN2 binds a small motif in the hinge domain of TRF2.  
(A) Schematic of human TRF2. The minimal Rap1 and TIN2 binding domains are 
indicated. Relevant TRF2 sequences from the indicated organisms surrounding the TIN2-
interacting domain were aligned with ClustalW. Boxes indicate identical amino acids. A 
conserved SQ site is shaded in pink. (B) Far western mapping the TRF2 TIN2-binding 
domain. Each lane contains lysate from induced E. coli BL21 bacterial cultures that 
express the indicated GST-fused TRF2 constructs. The lysates were subjected to SDS-
PAGE, stained with Coomassie blue (left), or blotted onto nitrocellulose and incubated 
with [35S]TIN2 IVT protein (right). UN, uninduced control; FL, full-length TRF2; ΔB, 
TRF2Δ1-42. (C) Co-IP of TIN2 with cotransfected wild-type and mutant TRF2. TRF2 
proteins are Myc-tagged and TIN2 proteins are HA-tagged. Myc 9E10 antibody was used 
for the IP. 
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In collaboration with the Lei laboratory (University of Michigan Medical 
School), we examined the TRF1TRFH-TIN2 and TRF2TRFH-TIN2 interfaces to 
determine why TIN2 prefers the TRFH domain of TRF1 over that of TRF2. 
In doing so, we learned that TRF1-interacting proteins contain an F-X-L-X-
P TRFH docking motif, while TRF2-interacting proteins have a Y-X-L-X-P 
TRFH localization sequence(15). 
Structural analysis of the TRF1TRFH-TIN2 interaction   
 To understand how TIN2 is recognized by TRF1TRFH, Lei and his 
colleagues first mapped the TIN2 TRFH-binding motif, TIN2TBM, to a short 
sequence (aa 256-276) in the C terminus of TIN2. They then crystallized the 
TRF1TRFH-TIN2TBM complex and solved its structure at 2.0 Å resolution(15). 
The electron density map shows that residues 257 to 268 of TIN2TBM assume 
a well-defined conformation. TRF1TRFH forms homodimers, and each 
TRF1TRFH interacts with one TIN2TBM peptide (Fig. 3-5A). TRF1TRFH 
exhibits essentially the same conformation as unliganded TRF1TRFH except 
for loop L34 (Fig. 3-5B). Loop L34 is partially disordered in the peptide-free 
structure. However, once TIN2TBM is bound, loop L34 folds back upon 
helices 3 and 4, sandwiched between the helices and TIN2TBM. 
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 Figure 3-5. Structure of the TRF1TRFH-TIN2TBM complex.  
(A) Overall structure of the dimeric TRF1TRFH-TIN2TBM complex. TRF1TRFH and 
TIN2TBM are colored in green and yellow, respectively, in one complex, and dark green 
and orange, respectively, in the other. (B) Superposition of the TRF1TRFH-TIN2TBM 
complex on the unliganded structure of TRF1TRFH. Loop L34 in the complex is in red and 
that of unliganded TRF1TRFH is in cyan, whereas the rest of TRF1TRFH is in green 
(TIN2TBM-bound) or gray (peptide-free). (Figure done by Lei group) 
 
 The structure of the complex reveals two adjacent but structurally 
distinct interaction modes (Fig. 3-6A, B). The N terminus of TIN2TBM 
(H257-F-N-L-A-P262) adopts an extended conformation stabilized by an 
extensive intermolecular hydrogen-bonding network. The side chain of L260 
is therefore positioned into a deep hydrophobic pocket of TRF1TRFH. In 
addition, F258 and P262 also make hydrophobic contacts with TRF1TRFH: 
F258 sits on a concave hydrophobic surface, whereas P262 stacks with 
TRF1-F142. In contrast, the C terminus of TIN2TBM (L263-G-R-R-R-V268) 
is positioned on the surface of loop L34 through formation of an antiparallel 
β sheet with D139-A-Q141 of TRF1TRFH so that R265-R-R267 of TIN2TBM 
contacts TRF1TRFH through electrostatic interactions. In particular, R266 is 
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nested within an acidic depression on the surface of loop L34 through a 
network of salt bridges and hydrogen bonds(15). 
 To investigate the importance of this TRF1-TIN2 interface, I 
performed co-IPs from 293T cells transiently expressing wild type and 
mutant forms of TIN2 and TRF1(15) (Fig 3-6C). Substitution of TIN2 L260 
with either an alanine or a glutamate abolished the interaction. By contrast, 
TIN2-P262A, designed to eliminate a stacking interaction with TRF1-F142, 
had a wild-type binding affinity, indicating that loss of this interaction is not 
essential for binding. However, substitution of TRF1-F142 with an alanine 
completely abrogated the binding to TIN2. These results were consistent 
with the in vitro isothermal titration calorimetry (ITC) binding data as 
measured by Lei and his colleagues(15). 
Structural analysis of the TRF2TRFH-TIN2 interaction 
 As discussed above, far western mapping of the TRF2-TIN2 
interaction suggested that binding of TIN2 to TRF2 is only mediated through 
the hinge domain of TRF2 and not the TRFH domain as is the case for 
TRF1. This result was consistent with co-IP studies; while mutation of 
TRF1-F142 to an alanine abolished TIN2 binding, TRF2-F120A (the 
structural equivalence of TRF1-F142A) interacted with TIN2 to the same 
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 Figure 3-6. The TRF1TRFH-TIN2TBM interface. 
(A) Schematic depiction of the TRF1TRFH-TIN2TBM interaction. The main-chain atoms of 
TIN2TBM are shown as circles [carbon in yellow (Cα in orange), oxygen in red, and 
nitrogen in blue]. Residues of TRF1TRFH are shown as green ovals (side-chain interaction) 
and square boxes (main-chain interaction). Hydrophilic and hydrophobic interactions are 
shown as straight magenta lines and curved red lines, respectively. The pale yellow 
arrows denote the intermolecular β sheet. (B) Electrostatic surface potential of the 
TIN2TBM binding site of TRF1TRFH. Positive potential, blue; negative potential, red. 
(Figures A and B done by Lei group) (C) Co-IP of wild type and mutant TRF1-TIN2 
interactions. TRF1 proteins are Myc-tagged and TIN2 proteins are HA-tagged. Myc 9E10 
antibody was used for the IP.  
 
extent as wild type TRF2(15) (Fig. 3-4C). Therefore, TRF2TRFH is not 
required for the stable association with TIN2 in vivo. ITC measurements 
showed that TIN2TBM interacts with TRF2TRFH in vitro, but with a much 
lower affinity (6.49 µM) than with TRF1TRFH (0.31 μM). The distinctive 
specificity of the TRFH domains of TRF1 and TRF2 suggested that subtle 
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structural differences are responsible for the ability of TIN2 to distinguish 
between these two paralogous proteins. To understand this binding 
specificity, the Lei lab solved the crystal structure of the TRF2TRFH-TIN2TBM 
complex at 2.15 Å resolution(15). Although the overall conformations of 
TIN2TBM bound to TRF1TRFH and TRF2TRFH are very similar (Fig. 3-7A), 
subtle differences can explain the difference in affinities of the two 
complexes. In the TRF1TRFH-TIN2TBM complex, TIN2-F258 sits snugly on a 
hydrophobic surface of TRF1TRFH (Fig. 3-7B). In contrast, F258 rotates away 
from the interface and packs less efficiently with TRF2TRFH, because the 
edge of the interaction surface is partially occupied by polar residues S98 
and R102 (Fig. 3-7B). In addition, TRF1-E192, which is key for TIN2TBM 
binding, is replaced by a lysine residue in TRF2 (K173), resulting in loss of 
two ion-pairing interactions and an electrostatically unfavorable contact 
between TIN2-R266 and TRF2-K173(15). 
Discussion 
 The data in this chapter show that TIN2 mediates an interaction 
between the TRF1 and TRF2 telomeric complexes. TIN2 binds the TRFH 
domain of TRF1 using a sequence that contains an F-X-L-X-P docking motif 
in its C terminus. Shelterin-associated proteins that bind the TRFH domain 
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Figure 3-7. Structure of the TRF2TRFH-TIN2TBM complex. 
(A) Superposition of the TIN2TBM binding sites in the TRF1TRFH-TIN2TBM and TRF2TRFH-
TIN2TBM complexes. TRF1TRFH and TRF2TRFH are in green and cyan, respectively. The 
TIN2TBM peptides bound to TRF1TRFH and TRF2TRFH are shown in stick model format 
and in yellow and magenta, respectively. (B) TIN2-F258 interacts less efficiently with 
TRF2 than with TRF1. The F258 binding surfaces of TRF1TRFH (top panel) and 
TRF2TRFH (bottom panel) are shown in magenta (hydrophobic patch) and blue 
(hydrophilic patch). The rest of TRF1TRFH and TRF2TRFH is in green and cyan, 
respectively. (Figure done by Lei group) 
 
 
of TRF2, such as Apollo, preferentially use a Y-X-L-X-P TRFH-docking 
motif. Hence, TIN2 has only a weak interaction with the TRFH domain of 
TRF2 in vitro(15). Instead, the major TRF2/TIN2 interface was mapped to the 
N terminus of TIN2 and a small region in the hinge domain of TRF2. With 
its separate TRF1 and TRF2 binding domains, TIN2 can interact with both 
of these shelterin proteins individually or simultaneously.  
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 The removal of TIN2 or TRF1 from telomeres leads to a concomitant 
loss of TRF2 and Rap1, suggesting that TIN2 plays an important role in 
stabilizing the TRF2 complex by tethering it to the TRF1 complex. 
Interactions between two DNA-binding proteins bound to neighboring sites 
will decrease the off rate of each and increase their affinity for DNA. Thus, 
the TIN2 link between TRF1 and TRF2 could increase the specificity of both 
proteins for telomeres. This effect may be particularly important with regard 
to TRF2, which has interactions with a number of abundant non-telomeric 
proteins, such as ATM, the Mre11 complex, and ERCC1/XPF. These 
interactions could lead to an inappropriate localization of TRF2 at non-
telomeric sites, for instance, when these factors accumulate at sites of DNA 
damage. The stabilization of the TRF2 complex by TIN2 tethering to TRF1 
may also explain the lethal phenotype of TRF1 and TIN2 deficiency in the 
mouse. A diminished TRF2 binding to telomeres in the absence of the 
TRF1/TIN2 stabilizing factor might result in telomere deprotection, which 
would impede cell proliferation. 
 In addition to binding to TRF1 and TRF2, TIN2 also interacts with 
TPP1, which serves to recruit POT1 to the telomeric complex. Because of its 
protein interactions, TIN2 connects the three main DNA binding activities at 
telomeres, two double-stranded DNA-binding proteins and the single single-
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stranded DNA binding factor. Furthermore, TIN2 tethers POT1 to TRF2 
independent of its interaction with TRF1, creating two separate protein 
interaction pathways by which POT1 can arrive at telomeres. Consistent with 
this, the binding of POT1 to telomeres is diminished by the inhibition of 
TRF2 as well as TRF1(76). We had previously suggested that the loss of 
POT1 from the telomeres after impaired TRF2 function could be because of 
the degradation of the single-stranded telomeric overhang(76). However, the 
current data suggest the loading of POT1 on telomeres could be affected by 
TRF2 inhibition in a manner that is not dependent on overhang degradation, 
but rather due to diminished loading of TIN2(47). 
 
 
Figure 3-8. TIN2 connects the three main DNA binding activities at telomeres. 
Schematic of how shelterin might be positioned on telomeric DNA, highlighting the 
duplex telomeric DNA interactions of TRF1 and TRF2 and the binding of POT1 to the 
single-stranded TTAGGG repeats. 
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 Creation of the TRF2 TIN2-binding mutant, TRF2ΔT, provides a 
reagent for exclusively studying the function of the TRF2-TIN2-TPP1-POT1 
complex at telomeres. This surgical mutation in the hinge domain of TRF2 is 
predicted to affect the TRF2-TIN2 connection while not interfering with the 
recruitment of TRF2-Rap1 or the TRF1-TIN2-TPP1-POT1 complex to 
chromosome ends. The experiments in the next chapter examine the 
phenotype of TRF2ΔT in mouse cells and provide insight into the function of 
the TRF2/TIN2 interaction.     
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CHAPTER 4: TIN2 ASSISTS TRF2 IN SUPPRESSING THE ATM-
DEPENDENT DNA DAMAGE RESPONSE AT TELOMERES  
Introduction 
 This chapter describes the phenotype of the mouse TRF2 TIN2-
binding mutant, mTRF2ΔT. Disruption of the association between TRF2 and 
the TIN2-TPP1-POT1 complex results in a unique ATM-dependent telomere 
damage response that leads to the induction of telomere dysfunction induced 
foci (TIFs) and changes in the status of the telomeric DNA. The nature of 
this response differs from that seen by loss of TRF2 or POT1 from 
telomeres. 
Telomere Protection by TRF2 
 TRF2 plays a key role in protecting telomeres from being recognized 
as sites of damaged DNA. This function of TRF2 was first elucidated in 
human cells using a dominant negative allele of TRF2, which lacks the N-
terminal basic domain and the C-terminal Myb DNA-binding domain 
(TRF2ΔBΔM). Uncapping of telomeres by TRF2ΔBΔM(122), RNAi(117), or by 
replicative telomere shortening(109) results in a myriad of consequences. One 
outcome of TRF2 loss is the accumulation of DNA damage response factors, 
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such as 53BP1, γ-H2AX, Rad17, phosphorylated ATM, and Mre11, at 
chromosome ends(28, 117). These entities are referred to as telomere 
dysfunction induced foci (TIFs)(117). Activation of the DNA damage 
response machinery at telomeres also triggers the induction of p53-mediated 
apoptosis or senescence, depending on cell type(55, 122). Additionally, 
deprotected telomeres cause degradation of the G-strand overhang by the 
nuclease ERCC1/XPF(122, 138). This event is a prerequisite for DNA Ligase 
IV-dependent nonhomologous end joining (NHEJ) at telomeres, resulting in 
end-to-end fusions and formation of dicentric and multicentric 
chromosomes(110, 122).  
 While TRF2ΔBΔM and RNAi were used to study the loss-of-TRF2 
phenotype in human cells, a novel system was developed in mouse cells.  
TRF2F/- mouse embryo fibroblasts (MEFs) were generated by deleting one 
allele of TRF2 and flanking the second TRF2 allele with LoxP sites, 
allowing inactivation of the TRF2 gene with Cre recombinase. Removal of 
TRF2 from these MEFs generates the same phenotypes as described above, 
including TIF formation, loss of the 3’ overhang, NHEJ-mediated telomere 
fusions, and cell cycle arrest(10).  
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 The DNA damage response elicited by deletion of TRF2 from 
mammalian cells is dependent on the ATM kinase. Ablation of TRF2 leads 
to autophosphorylation of ATM on S1981, a hallmark of ATM activation, 
and phosphorylation of the ATM target, Chk2(10, 66, 117). This response is 
thwarted when TRF2 is deleted from ATM-/- cells. The formation of TIFs 
and phosphorylation of Chk2 is largely abrogated(66).  
 How TRF2 inhibits ATM at telomeres remains to be determined. One 
possibility is that TRF2 promotes t-loop formation which tucks the 3’ 
overhang into the duplex region of the telomere, perhaps preventing it from 
being recognized and processed as a DNA break by ATM. In vitro t-loop 
assays using electron microscopy have shown that TRF2 is able to catalyze 
t-loop formation or to stabilize loops(42, 115), supporting this model. Another 
possibility is that TRF2 directly inhibits ATM activation. Evidence in favor 
of this model comes from the fact that TRF2 can actually binds ATM. 
Furthermore, overexpression of TRF2 hinders the response of ATM to DNA 
damage. TRF2 prevents autophosphorylation of ATM on S1981 and 
subsequent events associated with ATM activation such as phoshorylation of 
Nbs1, induction of p53 and its targets, and cell cycle arrest(56). Finally, it is 
possible that the suppression of ATM at telomeres is mediated by TRF2 
binding partners, such as Rap1, the Mre11 complex, or TIN2. 
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Telomere Protection by TPP1/POT1   
 Protecting chromosome ends is not solely the responsibility of TRF2. 
Shelterin’s single-stranded DNA binding protein, POT1, along with its 
recruiter, TPP1, are also major players in carrying out this function of 
telomeres(46-48, 129). Using RNAi studies in human cells, it was determined 
that POT1 loss leads to a transient DNA damage response that differs from 
that seen by TRF2 inhibition. Cells treated with POT1 shRNA have a 
reduction of the 3’ overhang and induce TIFs in G1, but lack a significant 
level of chromosome end fusions and fail to arrest(48).  
 In mouse cells, two POT1 proteins are required to fully protect 
telomeres. When both POT1a and POT1b are deleted, 70-80% of the nuclei 
contain DNA damage response factors at their telomeres, the cells 
experience a rapid proliferative arrest, and a mild telomere fusion phenotype 
is evoked. Single knockouts and complementation experiments indicate that 
POT1a is mainly responsible for repressing this DNA damage signal, while 
POT1b has a more specific role in regulating the structure of the telomere 
terminus(46). 
 Unlike TRF2, which represses the ATM kinase pathway at telomeres, 
POT1 is implicated in preventing ATR activation at chromosome ends. In 
agreement with this, POT1 deficiency initiates phosphorylation of Chk1 and 
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Chk2, downstream targets of ATR, while RNAi-mediated downregulation of 
ATR protein levels abolishes the damage response. Consistent with ATR as 
the mediator of this response, ATM deficiency has no effect on the outcome 
of POT1 loss(66).  
 The repression of ATR activation by POT1 is speculated to be the 
result of POT1 preferentially binding to single-stranded telomeric DNA 
instead of RPA. RPA recognizes and localizes to single-stranded DNA at 
sites of damage and recruits the ATRIP/ATR complex(139). The 3’ G-
overhang or D-loop can serve as a substrate for RPA binding. However, 
according to the model, the sequence specificity and high abundance of 
POT1 at chromosome ends allows POT1 to compete with RPA for these 
DNA sites.  
Telomere Protection by TIN2 
 TIN2 interacts with TRF1 and TRF2 independently or simultaneously, 
acting as a bridge linking TRF1 and TRF2 to TPP1 and POT1. Removal of 
TIN2 from telomeres by RNAi or expression of TIN2 mutants that fail to 
bind TRF1 or TRF2 results in a DNA damage response(61, 134). However, 
these methods for depleting TIN2 result in the destabilization of TRF1 and 
TRF2, and presumably TPP1/POT1 from telomeres, thus masking the 
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phenotype of a DNA damage response initiated exclusively by TIN2. To 
circumvent this problem, a surgical mutation was made in the hinge domain 
of TRF2 that prevents TIN2 binding. This TRF2 mutant, TRF2ΔT, still 
localizes to telomeres, as does Rap1 and TRF1. The experiments in this 
chapter were designed to examine the phenotype of TRF2ΔT and shed light 
on a novel ATM-dependent TIN2-mediated DNA damage response.  
Results 
Expression of TRFΔT in TRF2F/- p53-/- MEFs  
 Amino acids 350-365 in the hinge domain of mouse TRF2 were 
deleted using the same strategy that was employed to create human TRF2ΔT. 
Far western assaying verified that mouse TRF2ΔT does not bind TIN2 
whereas TRF2WT showed a strong interaction with the 35S-labeled protein 
(Fig. 4-1). 
 To study the phenotype of TRF2ΔT in vivo, Myc-tagged TRF2ΔT, 
along with Myc-tagged wild type TRF2 and empty vector, were introduced 
into TRF2F/- p53-/- MEFs by retroviral infection. p53-deficient MEFs were 
used to overcome the senescence-like arrest associated with TRF2 loss, 
allowing for analysis of mitotic chromosomes. Examination of TRF2ΔT cells 
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 Figure 4-1. mTRF2ΔT does not bind TIN2.  
Far western analysis of mTRF2ΔT with [35S]TIN2 IVT protein. Each lane contains lysate 
from induced E. coli BL21 bacterial cultures that express the indicated GST-fused 
mTRF2ΔB constructs. The lysates were subjected to SDS-PAGE, stained with Coomassie 
blue (left), or blotted onto nitrocellulose and incubated with [35S]TIN2 IVT protein 
(right). ΔB, mTRF2Δ1-45; UN, uninduced control; WT, wild type mTRF2; ΔT, 
mTRF2Δ350-365.  
 
by Myc IF revealed a mixed population of cells, with some exhibiting a mild 
to robust punctate staining that localized to telomeres and others presenting a 
diffuse nuclear staining (data not shown). The latter cells clearly were not 
localizing TRF2ΔT to telomeres. It became evident that abating the 
interaction between TIN2 and TRF2 was destabilizing TRF2 at telomeres. 
Use of these batch cells for analysis of the TRF2ΔT phenotype would be 
troublesome, as some of the cells would exhibit a loss-of-TRF2 phenotype. 
In order to circumvent this problem, we created clonal cell lines that  
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homogeneously expressed TRF2ΔT at a moderate to high level. After two  
rounds of cloning, one from retrovirally-infected cells and one from cells 
infected with lentivirus, four TRF2ΔT clones (TRF2ΔT-6, TRF2ΔT-21, TRF2ΔT-
13, and TRF2ΔT-16) were chosen for further examination based on their 
western blot and IF profiles (Fig. 4-2B, C). The following experiments were 
done in a setting where the floxed allele of TRF2 was deleted from cells by 
retroviral expression of Cre recombinase. This technology allows for 
analysis of the TRF2ΔT phenotype in the absence of endogenous TRF2. 
Indeed, western blotting showed that endogenous TRF2 was deleted from 
cells 96 hours post Cre infection in the TRF2ΔT clones as well as in vector 
and wild type cells (Fig. 4-2A, B).  
TRF2ΔT MEFs do not arrest 
 The majority of the experiments conducted in this chapter were done 
in the time frame of 72-120 hours post Cre expression. During this time 
frame, TRF2F/- p53-/- MEFs devoid of TRF2 experience growth defects with 
cells becoming large and flattened, eventually ending in death of the culture. 
At 120 hours, there was no evidence of growth arrest or changes in the 
morphology of the TRF2ΔT cells. We continued to grow the cells for an 
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Figure 4-2. TRF2F/- p53-/- clonal cell lines expressing TRF2ΔT.  
(A) Experimental timeline. (B) Western blot of cell lysates derived from TRF2ΔT clones. 
Cells were infected with Cre retrovirus and harvested 96 hours later. Anti-TRF2, 1254 
antibody was used; TRF2 and non-specific bands are indicated. (C) IF of TRF2ΔT clones. 
Antibodies used: anti-c-Myc, Sigma and anti-mTRF1, 644. 
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extended period of time to evaluate the proliferative potential of these 
MEFs. However, a western blot performed approximately two weeks post 
Cre infection revealed expression of endogenous TRF2 (data not shown). 
This suggested that there was a positive selection for cells that had not been 
exposed to Cre. To circumvent this problem, secondary clones of TRF2ΔT-13 
and TRF2ΔT-16 were made after the cells had been treated with Cre. Two 
clones for each were chosen for growth analysis. Western blotting revealed 
that after 42 days from the start of the growth curve, endogenous TRF2 was 
still deleted from these clones, while exogenous Myc-tagged TRF2ΔT 
continued to be expressed (Fig. 4-3). As the growth curve shows, there were 
no major growth defects in any of the clones analyzed (Fig. 4-3). The 
TRF2ΔT-13 clones, regardless of their Cre status, grew at similar rates, while  
the TRF2ΔT-16 Cre-positive clones proliferated somewhat slower than the 
Cre-negative control. It is possible that these clones were expressing such a 
high level of Cre that it was slightly toxic to the cells.  
Shelterin localization in TRF2ΔT MEFs  
 Based on far western assaying and 293T co-immunoprecipitation, it 
was shown that the association of TRF2ΔT with TIN2 was hindered. In order 
to determine the amount of TIN2 localizing to telomeres, the TRF2ΔT clones 
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 Figure 4-3. TRF2ΔT clones do not have growth defects.  
Graph of growth curves of Cre-positive secondary TRF2ΔT clones and the Cre-negative 
controls. TRF2ΔT-13 TRF2ΔT-16 clones were infected with retroviral Cre, selected in 
hygromycin for 5 days, clonal populations were isolated, and Cre-positive clones were 
chosen. Growth of the secondary clones was monitored for 70 days. Western blot shows 
that endogenous TRF2 was still inhibited after 42 days from the start of the growth curve, 
while exogenous TRF2ΔT was still expressed. endo, endogenousTRF2; exo, exogenous 
Myc-tagged TRF2ΔT. 
 
were examined by IF. This required the production of an antibody against 
mouse TIN2. TIN2 was cloned from a mouse cDNA library into a GST-
tagged E. coli protein expression vector. GST-mTIN2 was affinity-purified 
from induced BL21 bacterial cultures (Fig. 4-4A) and sent to Covance for 
polyclonal antibody production in rabbits. Upon receipt of the serum, the 
antibody was affinity-purified and tested by western blotting and IF. The 
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western blot revealed that mTIN2 1447 recognizes overexpressed Myc-
tagged mTIN2 and recombinant GST-mTIN2 protein, but not a discernable 
band for the endogenous protein (Fig. 4-4B). There was no reduction in 
proteins levels around the 50 kD marker in the lanes of MEFs treated with 
mTIN2 shRNAs compared to the lane of cells treated with the control 
luciferase shRNA (Takai, K and de Lange, unpublished). On the contrary, 
the antibody was successful in distinguishing endogenous mTIN2 by IF. 
TIN2 1447 elicited a robust punctate signal that co-localized with telomeric 
DNA at telomeres (Fig. 4-4C). This signal was greatly reduced in many of 
the cells treated with the same TIN2 shRNAs that were used for the western 
blot (data not shown) (Takai, K and de Lange, unpublished).  
 With this reagent in hand, we investigated the effect of TRF2ΔT 
expression on TIN2 localization to telomeres after deletion of endogenous 
TRF2. The TRF2ΔT clones, along with the TRF2WT control, were infected 
with Cre retrovirus four times every twelve hours, selected in media 
containing hygromyocin, and then harvested for immunofluorescence-
fluorescence in-situ hybridization (IF-FISH) analysis 96 hours post Cre 
infection. In the cells expressing TRF2WT, there was a strong TIN2 signal 
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 Figure 4-4. Antibody against mouse TIN2.  
(A) Coomassie-gel of affinity-purified GST-mTIN2. UN, uninduced; IN; input; FT, flow-
through; W, wash; E, elution. (B) Western blot using mTIN2 1447. Endogenous mTIN2, 
with shRNA-mediated knockdown (sh1 and sh2) or without (Luc, luciferase shRNA), 
overexpressed Myc-tagged mTIN2 (OE), and recombinant GST-mTIN2 (Rec) were 
tested. (C) IF of endogenous mTIN2 at telomeres. Telomeres were detected by FISH 
using a PNA probe specific for telomeric repeats (TTAGGG). 
 
that completely localized to telomeres based on the merged image with the 
telomeric TTAGGG PNA probe. However, a different pattern of TIN2 
signals was evident for the TRF2ΔT clones. In these cells, TIN2 gave a 
diffuse nuclear staining, with several dampened telomeric signals, 
suggesting that some TIN2 remains at telomeres through its interaction with 
TRF1 (Fig. 4-5). Similarly, the majority of POT1a did not localize to 
telomeres in cells expressing TRF2ΔT. In fact, the nucleus of these cells 
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appeared almost vacant, with little to no POT1a staining, except for a few 
extremely weak telomeric signals  (Fig. 4-6A). It is important to point out 
that this POT1a antibody is suboptimal for IF procedures; as such, it is 
possible that the amount of POT1a remaining at telomeres was below the 
detection level of the antibody.  
 Although TIN2 was substantially destabilized at telomeres in TRF2ΔT 
cells, we verified by IF-FISH that TRF1 and Rap1 are still localized to 
telomeres using TRF2ΔT-13 as an example (Fig. 4-6B, C). However, there was 
a noticeable increase in the amount of nucleoplasmic Rap1, and to a much 
lesser extent, TRF1, suggesting that some Rap1 and TRF1 is displaced from 
chromosome ends. We used telomere-specific ChIP to quantify the 
percentage of shelterin components at telomeres in the wild type and mutant 
settings. TRF2WT and TRF2ΔT-13 MEFs were infected with Cre and processed 
for ChIP analysis 120 hours later. The results indicated that there was 
approximately a 30-50% reduction in the amount of TRF1, TRF2, TIN2, and 
Rap1 at telomeres in TRF2ΔT-13 cells (Fig. 4-6D, E). For TPP1, POT1a, and 
POT1b, the overall amounts of precipitated proteins were too low to 
determine whether there was a significant difference between wild type and 
mutant cells. Combining the findings of the IF and ChIP experiments, we 
could presume that all components of shelterin are present at telomeres to 
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 Figure 4-5. Less TIN2 is localized to telomeres in TRF2ΔT clones.  
IF of TIN2 localization to telomeres in TRF2ΔT clones and the wild-type control 96 hours 
post Cre infection. TIN2 was detected with anti-TIN2, 1447 and telomeres were detected 
by FISH using a PNA probe specific for telomeric repeats (TTAGGG). White arrows 
indicate the few TIN2 signals that co-localize with telomeres in TRF2ΔT cells.  
75 
 
some degree except for the TIN2-TPP1-POT1 complex that associates with 
TRF2. This makes TRF2ΔT an attractive reagent for studying the function of 
this complex. Although, it cannot be ruled out that the reduction in TRF1, 
TRF2, or Rap1 may contribute to the phenotype of this mutant.  
TRF2ΔT MEFs induced TIFs  
 We treated TRF2WT and TRF2ΔT MEFs with retroviral Cre and 
examined the cells for TIFs, using 53BP1 staining, 96 hours later. Whereas 
the MEFs rescued with wild type TRF2 presented only a small background 
percentage of cells with five or more TIFs (6%), TRF2ΔT-6, TRF2ΔT-21, and 
TRF2ΔT-13 elicited TIFs in 86%, 71%, and 42% of the cells scored, 
respectively (Fig. 4-7). These TIFs varied in morphology and frequency 
when compared to TIFs induced by loss of TRF2. The 53BP1 foci in the 
TRF2ΔT clones appeared much larger, extending far beyond the telomeres, 
and TIFs occurred at fewer telomeres. Cells suffering from loss of TRF2 
have approximately 80% TIF-positive telomeres, while TRF2ΔT cells gave 
an average of 21% TIF-positive telomeres (Fig. 4-7). 
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 Although the majority of 53BP1 foci co-localized with telomeres 96 
hours post Cre expression, some foci were present in regions of nuclei 
completely devoid of telomeric signals. These telomere-less foci became  
 
Figure 4-6. Localization of shelterin components to telomeres in TRF2ΔT clones.  
IF of POT1a (A), TRF1 (B), and Rap1 (C) localization to telomeres in TRF2ΔT-13 cells 
and the wild type control 96 hours post Cre infection. Antibodies used: mouse anti-
POT1a; anti-TRF1, 644; anti-Rap1, 1252. Telomeres were detected by FISH using a 
PNA probe specific for telomeric repeats (TTAGGG). (D) ChIP of shelterin proteins at 
telomeres in TRF2WT and TRF2ΔT-13 cells. ChIP was performed on the indicated cell lines 
96 hours after introduction of Cre. Immunoprecipitated DNA was blotted onto a 
membrane and probed with the telomere specific γ-32P end-labeled oligonucleotide probe 
(CCCTAA)4. Antibodies used: anti-c-Myc, 9E10 (Calbiochem); anti-TRF1, 644; anti-
TRF2, 1254; anti-TIN2, 1447; anti-TPP1, 1150; anti-POT1a, 1221; anti-POT1b, 1223; 
anti-Rap1, 1252; PI, Pre-Immune serum (from animal used to generate Rap1 antibody 
1252). (E) Quantification of signals in (A). 
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even more prevalent at later time points. In fact, seven to ten days post Cre 
expression, the majority of 53BP1 foci were lacking a telomeric signal, thus 
rendering the number of TIF-positive cells insignificant. 
 
 
 
Figure 4-7. TRF2ΔT cells induce TIFs.  
IF of 53BP1 localization to telomeres in TRF2ΔT clones, TRF2WT cells, and the vector 
control. IF was preformed for 53BP1 (Novus) in conjunction with FISH using a PNA 
probe specific for telomeric repeats (TTAGGG) 96 hours after Cre infection. The 
percentage of cells with 5 or more TIFs and the percentage of TIF-positive telomeres are 
indicated for each. ND, not determined. 
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 ATM-mediated telomere damage response in TRF2ΔT MEFs 
 TRF2 and POT1 function independently to repress the activation of 
ATM and ATR kinases at natural chromosome ends. We asked whether the 
telomere damage response caused by expression of TRF2ΔT was ATM-
dependent. TRF2F/- ATM+/+ and TRF2F/- ATM-/- cell lines expressing 
TRF2ΔT were infected with Cre retrovirus and harvested for TIF and 
telomeric FISH analysis 72-120 hours later. Western blotting showed that 
TRF2ΔT was highly overexpressed compared to endogenous TRF2 and Cre 
deletion of the floxed allele was successful (Fig. 4-8A). In TRF2F/- ATM+/+ 
cells, expression of TRF2ΔT induced TIFs in approximately 30% of the 
nuclei scored (Fig. 4-8B). The number of TIF-positive cells was reduced by 
more than half to 13% in TRF2F/- ATM-/- MEFs expressing TRF2ΔT, 
suggesting the DNA damage response caused by TIN2 loss from the TRF2 
complex is, to some extent, an ATM-mediated event. This was supported by 
the fact that Chk2 was phosphorylated in TRF2ΔT TRF2F/- ATM+/+ cells after 
Cre treatment, but not in cells deficient in ATM. On the other hand, the MTS 
phenotype seemed to persist in the absence of ATM. These results were 
recapitulated, albeit to a lesser extent, in the TRF2ΔT-13 clone targeted with 
shRNA against ATM (Fig. 4-8D). In control cells treated just with an empty 
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vector, approximately 38% of the nuclei contained TIFs. When ATM protein 
levels were knocked down in the TRF2ΔT-13 MEFs, there was a mild 
reduction to 27% TIF-positive cells. It should be noted, however, that the 
shRNA-mediated decrease of ATM protein levels was not complete, and 
thus some ATM signaling was still occurring (Fig. 4-8C). 
 
Figure 4-8. Telomere dysfunction induced by loss of TIN2 from the TRF2 complex is 
partly ATM-dependent.  
(A) Immunblots for TRF2 and Chk2-P in TRF2F/- ATM+/+ and TRF2F/- ATM-/- MEFs 
expressing TRF2ΔT, TRF2WT, or the vector control. Cells were infected with Cre 
retrovirus and harvested 72 hours later. Antibodies used: anti-TRF2, 1254; anti-Chk2 
(BD Trans. Lab) (B) Quantification of TIF-positive cells in the indicated cell lines. (C) 
Immunblots for TRF2 and ATM in TRF2ΔT-13 cells treated with shATM or a vector 
control. Cells were infected with Cre retrovirus and harvested 96 hours later. Antibodies 
used: anti-TRF2, 1254; anti-ATM, MAT3 (Sigma) (B) Quantification of TIF-positive 
cells in the indicated cell lines. TIF-positive cells = cells with ≥ 5 TIFs.  
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Multiple telomeric signals and telomere loss at the ends of TRF2ΔT 
chromosomes  
 The induction of a DNA damage response at telomeres in TRF2ΔT 
MEFs prompted us to examine the status of the telomeric DNA. The 
condition of the telomeric overhang as well as the duplex telomeric DNA 
was evaluated using the in-gel hybridization method. Unlike the telomeres of 
the empty vector control cells, TRF2ΔT telomeres did not show signs of 
overhang loss or fusion events (Fig. 4-9).  
 
Figure 4-9. TRF2ΔT cells prevent overhang loss and fusions.  
In-gel hybridization assay examining single-stranded and duplex telomeric DNA in TRF2ΔT-
13 cells. Cells were harvested 120 hours post Cre infection; DNA was digested with MboI 
restriction endonuclease and subjected to PFGE. In-gel hybridization was performed under 
native conditions and the telomeric overhang was detected with the γ-32P end labeled 
oligonucleotide probe (CCCTAA)4 (Left).  DNA was denatured in situ and reprobed (Right). 
Overhang signal was quantitated using ImageQuant software and normalized to the total 
telomeric signal obtained after denaturation. The high molecular weight smearing seen in the 
denatured gel for the Cre-positive vector cells indicates fusion events. 
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 Concomitantly, analysis of the metaphase spreads of these cells by 
fluorescence in-situ hybridization (FISH) failed to reveal any significant 
chromosomal aberrations such as telomere fusions. We did, however, 
observe an approximately two-fold increase in the number of chromatid ends 
with two or more telomeric FISH signals (Fig. 4-10A, B). The number and 
intensity of these multiple telomeric signals (MTS) at a particular end 
varied, although the FISH signal we observed on a chromatid with multiple 
signals was roughly the sum of the sister signal, indicating that there was no 
loss or gain in the telomeric DNA content. Some MTS appeared as distinct 
doublets or multiples of equal or unequal intensity, while others failed to 
have a discrete shape, instead appearing as a spray or smear of signal at the 
chromatid end (Fig. 4-10A). Along with MTS, TRF2ΔT chromosomes also 
experienced a loss of telomeric signal (Fig. 4-10A, B) that was heightened 
under prolonged exposure to Cre, similarly to what was seen in interphase 
cells examined by IF-FISH. The number of signal-free ends (SFE) 96 hours 
post Cre expression was approximately five times higher in TRF2ΔT MEFs 
than in cells rescued by wild type TRF2 and approximately eight times 
higher one week post Cre expression (data not shown). It is not unlikely that 
MTS are a precursor to SFE.   
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Figure 4-10. TRF2ΔT cells have an increase in the occurrence of multiple telomeric 
signals and signal loss at chromatid ends.  
(A) Metaphase spreads illustrating the presence of multiple telomeric signals (MTS) and 
signal free ends (SFE) 96 hours post Cre expression. Metaphase spreads were obtained 
from the indicated cell lines and processed for telomeric FISH (green). DNA was stained 
with DAPI (false-colored in red). Enlarged images show examples of various MTS and 
SFE. (B) Quantification of MTS and SFE for the indicated cell lines.  
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Discussion 
 TIN2 binds TRF1 and TRF2 independently or simultaneously and 
serves as a linchpin, helping to anchor the shelterin complex at telomeres(61, 
134). We set out to determine the function of TIN2 in the TRF2 complex by 
creating a TIN2-binding TRF2 mutant, TRF2ΔT. The phenotype of TRF2ΔT 
was explored in vivo by expression of TRF2ΔT in TRF2F/- p53-/- MEFs. Since 
TRF2 is destabilized in the absence of TIN2, we initially encountered 
problems localizing TRF2ΔT to telomeres in batch-prepared cells. Clonal cell 
lines that homogenously expressed TRF2ΔT at relatively high levels at 
telomeres were created to study this TRF2 mutant. Shelterin protein levels 
were examined by telomere-specific IF and ChIP. IF analysis revealed that 
recruitment of TIN2 and POT1a to chromosome ends was severely 
dampened compared to wild type cells, whereas localization of TRF1 and 
Rap1 to telomeres seemed comparable to the wild type control, although 
some nucleoplasmic staining was apparent. ChIP data showed a reduction in 
all shelterin components, particularly TRF1, TRF2, and Rap1.  It is possible 
that a reduction in these protein levels could contribute to the phenotype of 
TRF2ΔT. Both TRF2ΔT cells and TRF1-/- MEFs see an increase in multiple 
telomeric signals at their chromatid ends (Sfeir and de Lange, unpublished), 
suggesting this phenotype could be attributed to the decrease in TRF1 at 
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telomeres. A reduction of TRF2/Rap1 is less likely to have an effect, 
considering that shRNA-mediated knockdown of TRF2, which also causes a 
decrease in Rap1 levels, has no effect on the ability of TRF2 to protect 
telomeres from an ATM-dependent DNA damage response (Takai, K and de 
Lange, unpublished). Hence, TRF2ΔT is a useful tool for studying the 
function of the TRF2-TIN2-TPP1-POT1 complex.  
 Depletion of TRF2 or POT1a/b from mouse cells results in 
proliferative arrest, changes to the telomeric overhang, and induction of a 
DNA damage response(10, 46). TRF2ΔT MEFs did not exhibit any overt growth 
defects or alterations in the single-stranded overhang. These cells did, 
however, elicit a DNA damage response that was monitored by TIF 
formation. The number of TIF-positive cells was subject to clonal variations. 
Three TRF2ΔT clones were scored for localization of 53BP1 foci to 
telomeres and had an average of 66% TIF-positive cells. Unlike TRF2-loss 
telomeres, not every TRF2ΔT telomere was decorated with 53BP1 foci, but 
for those that were, the foci extended far beyond the telomere. 
 The DNA damage response elicited by expression of TRF2ΔT is, in 
part, ATM-dependent. Loss of TIN2 from the TRF2 complex resulted in 
phosphorylation of Chk2 and a 2-fold reduction in the number of TIF-
positive cells in TRF2F/- ATM-/- cells. This suggests that TIN2 assists TRF2 
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in suppressing ATM at telomeres. We speculate that TRF2 may indirectly 
inhibit ATM by maintaining the chromosome end in a t-loop configuration, 
thus hiding the telomere from activating a DNA damage response. It is 
possible that TIN2 has a role in helping TRF2 carry out this function. 
Without TIN2, TRF2 may become promiscuous at maintaining the t-loop in 
its most protective state. In TRF2ΔT cells, the t-loop may be “loosened” 
occasionally, which may be enough to trigger a damage response, but not 
enough to lose the overhang or cause fusions, as when TRF2 is deleted. This 
might explain why only 15-20% of input DNAs are able to assemble into t-
loops by TRF2 in vitro(115). Perhaps the addition of TIN2 to this assay would 
increase the propensity of TRF2 to form t-loops.  
 TRF2 may also directly inhibit ATM. It has been shown that TRF2 
interacts with ATM, and overexpression of TRF2 has the ability to dampen 
the activation of the ATM kinase(56). It is possible that TIN2 strengthens this 
interaction between TRF2 and ATM, thus without TIN2, TRF2 fails to exert 
as much inhibitory pressure on ATM. Alternatively, ATM may bind TRF2 
in or around the same region as TIN2. As such, deletion of this small motif 
in the hinge domain of TRF2 could weaken or abrogate the TRF2/ATM 
interaction. Both of these possibilities are easily testable by co-IP analysis. 
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 Cells deficient in TRF2 also exhibit NHEJ-mediated telomere fusions. 
FISH analysis of metaphase spreads from TRF2ΔT MEFs did not yield 
fusions, but instead showed an increase in amount of MTS at chromatid ends 
as well as telomere loss. The occurrence of MTS has been reported 
previously in ATM-/- mouse cells(119), in unperturbed human fibroblasts and 
other human cells(94), in cells where the shelterin accessory factor, Apollo, 
has been knocked down(120), and in TRF1-/- MEFs (Sfeir and de Lange, 
unpublished). The nature and origin of these aberrant telomere structures has 
not been established. One hypothesis is that the MTS are recombined t-loops 
that are still attached to telomeres. However, preliminary experiments by 
van Overbeek and Sfeir to prove this have failed (unpublished data). Our 
current thinking is that MTS structures represent fragile sites. Fragile sites 
are loci, or regions, that are especially sensitive to forming gaps or breaks on 
metaphase chromosomes when DNA replication is perturbed(99, 116). They are 
frequently deleted or rearranged in many cancer cells(38). This deletion of the 
fragile site might be represented by the signal-free end. 
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CHAPTER 5: DISCUSSION  
 Telomeres prevent the ends of linear chromosomes from being 
recognized and processed as damaged DNA and are maintained by the 
enzyme telomerase. The six-protein complex that binds telomeric DNA, 
shelterin, is responsible for carrying out many of the functions of telomeres. 
Originally, shelterin components were viewed as members of separate 
complexes with the TRF1 complex acting to regulate telomere length and 
the TRF2 complex serving to protect telomeres. My research and that of 
others suggest that these two complexes do not only operate as individual 
units, but can also function as a single complex, with their connection 
mediated by the shelterin protein, TIN2. 
 In this thesis, I first examined the role of tankyrase1, a TRF1-
associated PARP, in telomere length regulation. I then set out to determine 
the role of TIN2 in the TRF2 complex after discovering that TIN2 was not 
only a TRF1-interacting protein, but was also bound to TRF2. My results 
implicate TIN2 in telomere protection. The discussion that follows below 
highlights my findings and their relevance to telomere biology. 
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The role of the poly(ADP-ribose) polymerase, tankyrase1, in telomere 
length control 
 Tankyrase1 RNAi resulted in telomere shortening that was 
proportional to the level of knockdown, validating that tankyrase1 is a 
positive regulator of telomere length. We also showed that a tankyrase1-
resistant form of TRF1 has no effect on the ability of TRF1 to regulate 
telomere length, implying tankyrase1 is not required downstream of TRF1. 
Finally, it was shown that tankyrase1 does not seem to have a role at mouse 
telomeres. It is possible that human cells evolved to include an additional 
level of control over telomere length that mice may not need because of their 
increased telomerase activity in somatic cells and their longer telomeres.  
 Interestingly, a divergence between human and mouse telomeres has 
also been seen for POT1. The mouse requires two POT1 proteins to properly 
protect the telomere and to regulate its length, while humans only have one 
POT1 protein that fulfills these functions(46). It is conceivable that as more 
shelterin-associated factors are discovered, there may be further examples of 
the rapid evolution of the telomere/telomerase system.  
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The role of TIN2 in the TRF2-TIN2-TPP1-POT1 Complex 
TIN2 interacts with TRF1 and TRF2 
 Co-IP experiments revealed there was a link between the TRF1 and 
TRF2 complexes, and RNAi studies showed that a reduction in the amount 
of TRF1 or TIN2 protein levels leads to a concomitant loss of TRF2 and 
Rap1 from telomeres(134). Gel filtration verified these results demonstrating 
that telomeric proteins exist in a single complex and that TIN2/POT1 is a 
component of the TRF2 complex. Far western analysis revealed that TIN2 
directly binds TRF2, and TIN2 can associate with TRF1 and TRF2 
simultaneously(134). This interaction is thought to stabilize shelterin on 
telomeres(61, 134). This stabilization is particularly important for TRF2 given 
the number of interactions this protein has with non-telomeric factors, 
especially DNA damage/repair proteins. 
 Crystallography studies and far western mapping determined that 
TIN2 binds the TRFH domain of TRF1 using an F-X-L-X-P docking motif 
in its C-terminus while the N-terminus of TIN2 associates with a small 
sequence in the hinge domain of TRF2(15). TIN2 has only a weak interaction 
with the TRFH domain of TRF2, despite the fact that the TRFH domains of 
TRF1 and TRF2 have almost identical three-dimensional structures(15, 36). 
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Instead, many proteins that associate with TRF2 contain a Y-X-L-X-P 
TRFH-docking motif, including Apollo, ERCC1/XPF, ATM, ATR, PARP1, 
and Nbs1. Except for Apollo, which was shown to have a strong affinity for 
the TRF2-TRFH domain(15), it remains to be determined whether these 
factors actually use this motif to bind TRF2. Co-IP analysis coupled with 
mutational and structural studies would be useful in this regard. Once it is 
determined which proteins use this motif to bind TRF2, the interactions can 
be disrupted and the phenotypes associated with loss of these TRF2-
associating factors can be evaluated. The same experiments can be 
implemented for TRF1 and the proteins that potentially bind TRF1 using the 
F-X-L-X-P docking sequence.  
 It would also be interesting to see if swapping of the TRF1 TRFH-
binding motif (TRF1TBM) for the TRF2TBM forces proteins that usually 
associate with TRF1 to now bind TRF2, or vice-versa. Determining whether 
these factors are still recruited to telomeres and examining the consequences 
of switching their binding partners may provide insight into these 
TRF1/TRF2 protein interactions. It would also be important to establish 
whether these artificial associations disrupt other naturally occurring 
interactions at this interface. It is conceivable that a protein forced to interact 
with TRF2 instead of TRF1 could compete for TRF2 TRFH binding sites 
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that would normally be available to known TRF2 binding partners, or vice-
versa. 
Expression of TRF2ΔT induces a DNA damage response 
 After mapping the major TIN2-binding domain in TRF2, this small 
sequence was deleted from TRF2, creating the mutant, TRF2ΔT. The 
phenotype of this mutant was examined in TRF2F/- p53-/- MEFs, where 
endogenous TRF2 could be deleted by infection with Cre recombinase. By 
co-IP and IF analysis, there was a significant reduction in the amount of 
TIN2 bound to TRF2 and localized to telomeres. Expression of TRF2ΔT also 
elicited a DNA damage response that was characterized by telomere 
dysfunction induced foci (TIF) formation, but not overhang loss or growth 
arrest. These TIFs appeared at fewer telomeres and were much larger than 
the TIFs induced upon inhibition of TRF2 or POT1. All of the TIF analysis 
done in this study used 53BP1 as an indicator of damaged DNA. Upon 
deletion of TRF2, a number of DNA damage response factors have been 
shown to localize to telomeres, including γ-H2AX, phosphorylated Rad17, 
phosphorylated ATM, MDC1, and members of the Mre11 complex(27, 117). 
Determining which damage/repair proteins localize to telomeres would be 
informative in distinguishing the type of damage induced by TRF2ΔT.  
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 The TIFs induced by expression of TRF2ΔT are, in part, ATM-
dependent. The number of TIF-positive cells is reduced by more than half 
when TRF2ΔT is expressed in ATM-/- cells. However, the fact that TIF 
formation is not completely abrogated suggests another DNA damage 
signaling pathway is at play in these cells. ChIP and IF data revealed that in 
addition to a decrease in TIN2, TRF2ΔT telomeres also suffer a reduction in 
the number of Rap1, TRF1, and POT1 molecules. Loss of TRF1 or POT1 
induces a DNA damage response that is dependent on ATR(66) (Sfeir and de 
Lange, unpublished). Perhaps the reduction in TRF1/POT1 in the TRF2ΔT 
MEFs is enough to trigger this response, and thus the TIFs persisting in the 
ATM-/- cells are a result of ATR activation. Expression of an ATR shRNA in 
the TRF2ΔT ATM-/- cells or inhibition of both ATM and ATR by caffeine or 
wortmannin would address this matter. Similarly, TRF1/POT1 could be 
overexpressed in the TRF2ΔT ATM-/- cells to see if this rescues the remaining 
TIFs.  
How does the TRF2-TIN2 interaction inhibit ATM? 
 Having shown that the DNA damage response elicited by TRF2ΔT is, 
to a certain extent, ATM-dependent, we hypothesized how TIN2 could assist 
TRF2 in suppressing ATM activation at telomeres. One possibility is that 
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TRF2 needs TIN2 for efficient t-loop maintenance. TIN2 stimulates the 
ability of TRF1 to induce pairing or higher-order interactions between 
telomeric DNA tracts by causing a conformational change in TRF1. It is 
possible that TIN2 can also stimulate the ability of TRF2 to rearrange 
telomeric DNA into t-loops. The structure of the t-loop is proposed to hide 
the 3’ overhang, preventing a DNA damage response. In TRF2ΔT cells, the t-
loop may be compromised to some extent, triggering a damage response. 
TIN2 could be added to an in vitro t-loop formation assay to see if there is 
an increase in the number TRF2-promoted t-loops. 
 TIN2 may also work with TRF2 to inhibit ATM directly. TRF2 has 
been shown to bind ATM, and overexpression of TRF2 suppresses ATM 
activation(56). TIN2 may enhance this interaction between TRF2 and ATM, 
or it plausible that ATM binds TRF2 in the same region as TIN2, thus 
expression of TRF2ΔT would alleviate the inhibitory pressure on ATM and 
activate a damage response. One final possibility is that TIN2 directly 
inhibits ATM. Co-IP analysis could be implemented to test these models. 
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TRF2ΔT MEFs do not yield telomere fusions, but multiple telomeric signals 
and telomere loss 
 Loss of TRF2 results in the formation of telomere end-to-end fusions 
that are mediated by the NHEJ pathway(10, 11, 66, 110, 122). TRF2ΔT MEFs, on the 
other hand, did not yield chromosome fusions. It is possible that the 
presence of TRF2/Rap1 at telomeres was enough to block NHEJ. This is 
supported by in vitro data showing that Rap1 could prevent end-joining of 
short telomere arrays(2). Although no fusions were observed, we did detect a 
significant increase in the number of multiple telomeric signals (MTS) at 
chromatid ends as well as telomere loss in cells expressing TRF2ΔT. MTS 
have also been seen in cells where the TRF2-interacting protein, Apollo, has 
been knocked down as well as in TRF1-/- MEFs(120) (Sfeir and de Lange, 
unpublished). It remains to be determined what exactly these MTS structures 
represent, but one possibility is that they are fragile sites. Fragile sites are 
chromosomal regions that are particularly sensitive to forming gaps or 
breaks on metaphase chromosomes after partial inhibition of DNA 
replication(99, 116). Treatment with the DNA replication inhibitor aphidicolin 
induces the expression of fragile sites(39). It would be interesting to see if the 
addition of aphidicolin to TRF2ΔT cells increases the number of MTS. 
Moreover, fragile sites are frequently deleted or rearranged in many cancer 
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cells(38). A similar fragile site-induced deletion might be occurring in 
TRF2ΔT cells, which may be represented as signal-free ends. What causes 
these deletions remains to be determined, but one possibility is they are a 
result of unequal or faulty homologous recombination of stalled replication 
forks.    
 There is no discernable difference between ATM-deficient cells and 
control cells in spontaneous or aphidicolin-induced chromosome gaps or 
breaks at fragile sites. However, ATR-deficient cells show a highly 
significant increase in gaps and breaks at fragile sites both with or without 
the addition of replication inhibitors(38). The fact that the TRF2ΔT MTS 
phenotype remained unchanged in ATM-/- cells supports the claim that these 
structures are fragile sites. To further support this claim, the TRF2ΔT MTS 
phenotype should be examined in the absence of ATR. Without ATR to 
stabilize the fragile site, it is likely that the severity of MTS would increase.   
Is the TRF2-TIN2 interaction determined by TRF2’s phosphorylation status? 
 Recent work by Hoke and de Lange revealed that TRF2 is 
phosphorylated at Serine 368 (S368) by the ATR kinase, and 
phosphorylation of this site plays a role in relieving replication stress at the 
telomere (unpublished). S368 lies directly adjacent to the TRF2 TIN2-
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binding motif (352-367) (Fig. 3-4A), suggesting that the phosphorylation 
status of TRF2 might regulate its interaction with TIN2. In fact, it was 
shown that the phosphomimetic mutation, S368E, causes a slight reduction 
in the amount of TIN2 associated with TRF2 while the S368G mutant, 
which mimics the unphosphorylated state of TRF2, leads to increased 
binding to TIN2 (Hoke and de Lange, unpublished). Considering that a 
residual amount of TIN2 still interacts with TRF2ΔT (Fig. 3-4C), it may be 
worthwhile to make the double mutation, TRF2ΔT-S368E, to diminish this 
interaction even further, if not completely. Perhaps this double mutation 
would have a stronger DNA damage phenotype than TRF2ΔT alone. 
TIN2 and Dyskeratosis Congenita 
 Dyskeratosis congenita (DC) is an inherited bone marrow failure 
syndrome characterized by nail atrophy, skin hyperpigmentation, and oral 
leukoplakia. Patients with DC have abnormally short telomeres, 
chromosome instability, and a predisposition to develop certain cancers(33, 
83). DC has been correlated to mutations in hTERT, hTERC, dyskerin, and 
NOP10, a component of H/ACA snoRNP complexes(83, 124, 125, 132), however, 
approximately 60% of DC patients lack an identifiable mutation(81). A 
linkage scan was performed on a family with autosomal-dominant DC that 
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lacked mutations in telomerase, and interestingly, mutations were linked to 
TIN2(96).  These mutations were mapped to a highly conserved region of 
TIN2, just outside of the TRFH-binding motif (aa 256-276)(15), and include 
the following substitutions: K280E, R282S, and R282H. Given the close 
proximity of these mutations to the TRF1-TRFH binding motif, it is 
conceivable that altering these amino acids could affect the ability of TIN2 
to bind TRF1. This would lead to the destabilization of shelterin and 
telomere dysfunction. However, our preliminary co-IP data suggests that 
these TIN2 mutants interact with TRF1 to the same extent as the wild-type 
control (unpublished). The three-dimensional structure of mutated TIN2 
with TRF1 would be useful for reconciling this model.  
 Despite the fact that TPP1 associates with the N terminus of TIN2 and 
not near the mutation sites, it may be possible that the mutated TIN2 has an 
aberrant interaction with TPP1. Recent data indicates that the TPP1/POT1 
complex may contribute to the recruitment of telomerase. In fact, TPP1 has a 
direct interaction with telomerase and has been shown to increase the 
activity and processivity of the enzyme when complexed with POT1(126, 130). 
Perhaps, mutation of TIN2 affects the recruitment or stability of TPP1. 
Consequently, TPP1 may fail to properly recruit telomerase, thus causing the 
short telomere phenotype associated with DC. Co-IP analysis of the TIN2-
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TPP1 interaction would shed light on this possibility. It also cannot be ruled 
out that TIN2 itself has a role in recruiting telomerase, and these mutations 
may inhibit this function.  
 One final explanation is that TIN2 associates with a yet-to-be 
identified protein, and mutation of this region in TIN2 disrupts the 
interaction, leading to telomere instability and the onset of DC. While the 
reason these TIN2 mutants cause DC remains to be determined, it should be 
noted that TIN2 is the first shelterin component to be mutated in human 
disease. 
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MATERIALS AND METHODS 
Cell culture 
Phoenix ecotropic and amphotrophic packaging cell lines, 293T cells, HeLa 
1.2.11 cells, and p53-/- and SV40 transformed MEFs were grown in DMEM 
supplemented with 100 U/ml penicillin (Sigma), 0.1 μg/ml of streptomycin 
(Sigma), 2.0 mM L-glutamine (Invitrogen), 0.1 mM non-essential amino 
acids (Invitrogen), and 10% Fetal Bovine Serum. BJ fibroblasts (Clontech) 
were grown in 4:1 DMEM/199 media supplemented with 15% fetal bovine 
serum, 100 U/ml penicillin (Sigma), 0.1 μg/ml of streptomycin (Sigma), 2.0 
mM L-glutamine (Invitrogen), 0.1 mM non-essential amino acids 
(Invitrogen), and 1 mM sodium pyruvate (Sigma). All cells were grown at 
37°C, 5% CO2, and 95% relative humidity. Cells were passaged by pre-
rinsing with room temperature Trypsin-EDTA (Gibco, 0.25%) followed by 
incubation in Trypsin-EDTA for 2-5min. Cells were seeded as indicated in 
text. Cells were counted with a Counter Counter Z1 Particle counter. For 
growth curves, 300,000 cells were plated on a 10 cm dish and grown for 
approximately 72 hrs Cells were harvested using trypsin and recovered in 4 
ml of media, and the total cell number was determined. 300,000 cells were 
plated in a new 10 cm dish. At specified times, extra cells were plated in 
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order to obtain protein and DNA samples for analysis. Population doublings 
were determined by the following formula: PD = original PD + [ln(# cells at 
passage/#cells seeded)/ln(2)] using Excel. 
Calcium phosphate transfection of 293T cells 
One day prior to transfection, 2 x 106 293T cells were plated in 10 cm 
dishes. Cells were transfected with 10 μg of the appropriate plasmid using 
CaPO4 co-precipitation. For each plate, 428 μl H20, 62 μl 2M CaCl2, and 10 
μg plasmid DNA was mixed with an equal amount of 2X HBS (50 mM 
HEPES pH 7.05, 10 mM KCl, 12 mM dextrose, 280 mM NaCl, 1.5 mM 
Na2PO4) while lightly vortexing. Media was refreshed 5-8 hrs after 
transfection. 48 hrs after transfection, cells were harvested in media, 
counted, washed with PBS, and resuspended in 200-500 μl of lysis buffer 
(50 mM Tris-HCl pH 7.4, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT, 1 mM PMSF, with a completemini-protease 
inhibitor tablet [Roche] per 10 ml). The NaCl concentration was raised to 
400 mM (this step was removed for the salt-sensitive TRF2/TIN co-IPs), and 
the lysate was incubated on ice for 20 min. The NaCl concentration was 
reduced in half with an equal volume of cold water, and cell debris was 
removed by centrifugation at 13K for 10 min at 4°C.  
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Immunoprecipitation 
For immunoprecipitation of proteins expressed by transient transfection in 
293T cells, transfection and harvesting was performed as above. 50 μL of 
2X Laemmli buffer was added to 50 μL of lysate and set aside as the 
“Input.” Antibody (2 μL of affinity purified and commercial antibodies, 10 
μL of crude serum) was added to 400 μL of lysate. Samples were nutated at 
4°C for 5 hrs. 60 μL of a Protein G sepharose slurry (50% [v/v] Protein-G 
sepharose [Amersham] in PBS in 1 mg/ml BSA) were added, and samples 
were nutated at 4°C for an additional 60 min. Beads were washed 3 times at 
4°C with lysis buffer, and immunoprecipitated protein was eluted with 60 
μL 2X Laemmli buffer. Samples were boiled for 5 min before loading onto 
SDS-PAGE gels.  
Retroviral gene delivery 
One day prior to transfection, 1 x 106 Phoenix packaging cells (293T derived 
cell lines) were plated in 10 cm dishes. For infection of mouse cells, Phoenix 
ecotropic cells were used. For infection of human cells, Phoenix 
amphotropic cells were used. Phoenix cells were transfected with 20 μg of 
the appropriate plasmid DNA by CaPO4 co-precipitation (described above). 
The media was refreshed 5-8 hrs later, and again 24 hrs later. 36 hrs after 
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transfection, media was filtered through a 0.4 μm filter and polybrene was 
added to a final concentration of 4 μg/mL. Fresh media was added to the 
virus producing cells. This procedure was repeated 3 additional times at 12 
hr intervals. If appropriate, 12 hrs after the final infection, fresh media was 
added containing antibiotics for selection (puromycin 2 μg/ml, hygromycin 
90 μg/ml) for 4-5 days until uninfected control cells were completely dead. 
Lentiviral gene delivery 
293T cells were transfected using calcium phosphate with 3 μg each of 
helper plasmids (pMDLg/RRE, pRSV-rev, and pCMV-VSVG) and 7 μg of 
lentiviral vector (pLenti6/Ubc/V5, Invitrogen) carrying the appropriate 
transgene per 10 cm dish. Fresh media was added 5-8 hrs after transfection. 
72 hrs after changing the media, virus-containing media was collected in a 
50 ml conical tube and centrifuged for 5 min at 1K rpm at 4°C. The virus 
was filtered through a 0.4 μm filter and polybrene was added to a final 
concentration of 4 μg/ml. 2x105 MEFs were plated for each infection, the 
day before infection. Half of the filtered virus was used for the initial 
infection. Remaining virus was kept on ice and used for a second infection 
12 hrs later. 12 hrs after the second infection, virus-containing medium was 
replaced with fresh medium. The following day, media was replaced with 
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media containing 6 μg/ml blasticidin. After four days of selection, 
blasticidin concentration was dropped to 2.5 μg/ml, and cells were selected 
for an additional 7 days. 
Isolation of clonal lines 
TRF2F/- MEFs expressing TRF2 alleles were plated at low density (500-2000 
cells/10 cm dish) and grown for approximately 2 weeks until clonal 
populations were visible under the light microscope. Clonal populations of 
cells were isolated by trypsinizing cells in cloning cylinders. Clonal 
populations were transferred to a well of a 96 well plate. When the cells 
reached confluence in the well, the clonal population was expanded. 
Expression of Cre recombinase 
Cre was introduced into MEFs using pMMP Hit & Run Cre-GFP 
retrovirus(104) or pWZL-Cre retrovirus (containing the hygromycin resistance 
gene) using the retroviral infection technique described above. 
shRNA 
shRNAs were made in pSUPER-retro (Oligo-Engine) and retroviral 
infections were performed as described above. The sequences of the shRNA 
targets are as follows:  
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Tank1 sh1; 5’-GGCAGTGGCAGTAACAATT-3’  
Tank1 sh3; 5’-GAGGTTGTGAGTCTGTTAT-3’ 
Tank1 sh4; 5’-GCGCTGATCCTACGTTAGT-3’  
Tank1 sh5; 5’-GCGTCGCTCTCAGCATCAT-3’ 
ATM sh3; 5’-GGAAGTCAAGGAACAACTA-3’ 
Whole cell lysates and western blots 
For whole cell lysates, cells were harvested, washed with PBS, counted and 
resuspended in 2X Laemmli buffer at a concentration of 5000 cells/μl. 
Lysates were boiled for 5 min and DNA was sheared through a 28-gauge 
insulin syringe. Protein samples were separated by SDS-PAGE and blotted 
onto nitrocellulose membranes. Membranes were blocked in 5% milk in 
PBST (0.5% Tween-20 in PBS) for 30 min at RT and nutated with primary 
antibodies in 0.1% milk in PBST overnight at 4°C. Membranes were washed 
3 times in PBST, nutated in secondary antibody in 0.1% milk in PBST for 
45 min at RT, and washed 3 times with PBST at RT. ECL (Amersham) was 
applied to membranes for 5 min before exposure to film. 
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Chromatin immunoprecipitation (ChIP) 
Cells were washed with PBS, fixed in 1% formaldehyde in PBS for 60 min 
at RT, washed in PBS, and lysed in 1% SDS, 50 mM Tris-HCl pH 8.0, 10 
mM EDTA at a density of 1x107 cells/ml. Lysates were sonicated on ice for 
10 cycles of 20 seconds each (0.5 seconds on/0.5 seconds off) on power 
setting 5 on a Misonix Sonicator 3000. Two 50 μl aliquots of lysates were 
set aside at 4°C to represent “Total” DNA. 200 μl of lysate was diluted with 
1.2 ml 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl 
pH 8.0, and 150 mM NaCl. Antibody (20 μl crude serum or 4 μl affinity 
purified antibody or anti-c-myc 9E10, see antibody section below for 
specifics) was added and cells were nutated overnight at 4°C. 30 μl protein 
G sepharose beads (Amersham; blocked with 30 μg BSA and 5 μg sheared 
E. coli DNA) was added and samples were nutated for an additional 30 min 
at 4°C. Beads were pelleted by centrifugation and pellets were washed with 
0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8.0, 20 mM Tris-HCl pH 
8.0, 150 mM NaCl. The second wash was the same except with 500 mM 
NaCl. Subsequent washes were with 0.25 M LiCl, 1% NP-40, 1% Na-
deoxycholate, 1 mM EDTA pH 8.0, 10 mM Tris-HCl pH 8.0, 1 mM EDTA. 
Chromatin was eluted from beads with 500 μl 1% SDS, 0.1M Na2CO3. 450 
μl 1% SDS, 0.1M Na2CO3 was added to the “Total” fractions, and these 
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were subsequently processed along with the rest of the samples. 20 μl 5M 
NaCl was added and samples were incubated for 4 hr at 65°C to reverse 
cross-links. At this point, 20 μl 1M Tris-HCl pH 6.5, 10 μl 0.5 M EDTA, 
and 20 μg DNase free RNase A was added and samples were incubated at 
37°C for 30 min 40 μg proteinase K was added and samples were digested 
for 60 min at 37°C and extracted with phenol. 20 μg of glycogen was added 
and samples were mixed. 1 ml ethanol was added and DNA was precipitated 
overnight at -20°C. Precipitated DNA was dissolved in 100 μl H20, 
denatured at 95°C for 5 min, and blotted onto Hybond membranes in 2X 
SSC (0.3M NaCl, 0.03M Sodium citrate). Membranes were treated with 
1.5M NaCl, 0.5 N NaOH for 10 min and then with 1 M NaCl, 0.5 M Tris-
HCl pH 7.0 for 10 min Hybridization was performed with a γ32-P end-labeled 
[CCCTAA]4 probe as described for in gel hybridization of genomic DNA. 
Membranes were washed 4 times in 2X SSC and exposed overnight to a 
PhosphorImager screen. Screens were developed using a STORM 820 
Phosphorimager (Molecular Dynamics). ImageQuant software was used to 
quantify the percent of total telomeric DNA that was precipitated by each 
antibody. 
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Co-IP of TRF1 and TRF2 from BJ-hTERT cells 
Cells were retrovirally infected with FLAG-tagged TRF1 or vector alone and 
were expanded on 15-cm plates. At confluency, cells were trypsinized, 
collected, washed in 10x pellet volume PBS, washed in 10x pellet volume 
resuspension buffer (10 mM Tris-HCl (pH 7.4), 60 mM NaCl, 5 mM MgCl2, 
0.5 mM EDTA, and 0.1 mM EGTA), and resuspended in 10x pellet volume 
lysis buffer (resuspension buffer with 0.2% Nonidet P-40, 1 mM 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and a complete 
protease inhibitor mixture tablet (Roche)). The cell lysate was kept on ice for 
10 min with occasional mixing, and the nuclei were collected by 
centrifugation, washed in resuspension buffer, and then resuspended in 3x 
pellet volume nuclear extraction buffer (20 mM Tris-HCl (pH 7.4), 400 mM 
NaCl, 0.5 mM EDTA, 0.2% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM 
phenylmethylsulfonyl fluoride, and a complete protease inhibitor mixture 
tablet). The nuclear extract was kept on ice for 30 min with occasional 
vortexing, the lysate (derived from 3 x 108 cells) was centrifuged, and the 
supernatant was diluted with an equal volume of water. The diluted 
supernatant was incubated with 100 µl (settled volume) of bovine serum 
albumin-blocked Sepharose 6B beads for 30 min at 4°C, centrifuged, 
removed from the beads, incubated with 100 µg/ml ethidium bromide for 20 
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min on ice (yielding the IP input), and then incubated with 100 µl (settled 
volume) of bovine serum albumin-blocked FLAG beads overnight at 4°C. 
Beads were washed four times with 1 ml wash buffer (20 mM Tris-HCl (pH 
7.4), 200 mM NaCl, 0.2 mM EDTA, 0.1% Nonidet P-40, 15% glycerol, and 
0.5 mM phenylmethylsulfonyl fluoride) and then incubated with 120 µl 
elution buffer (wash buffer with 0.2 mg/ml FLAG peptide). 
Preparation of genomic DNA 
Cells were harvested by trypsinization and washed with PBS. 0.5 X 106 cells 
for MEFs and 1 x 106 cells for BJ-hTERTs were resuspended in 50 μl PBS 
and incubated at 50°C for 5 min. Using pipette tips with the ends cut off, 50 
μl of 2% agarose (prewarmed to 50°C) was added to each sample, mixed, 
and incubated for 5 min at 50°C. The 100 μl mixture was added to the Bio-
Rad plug cast, incubated at RT for 5 min and at 4°C for 15 min. Solidified 
plugs were incubated in 0.5 ml Proteinase K digestion buffer (10 mM Tris-
HCl pH 7.9, 250 mM EDTA pH 8.0, 0.2% sodium deoxycholate, 1% sodium 
lauryl sarcosine, and 1 mg/ml fresh Proteinase K) overnight at 50°C. Plugs 
were washed three times with TE for one hr each at RT with nutation. Plugs 
were washed for 1 additional hr at RT with TE containing 1 mM PMSF and 
stored at 4°C in this final wash. Prior to digestion, plugs were washed for 1 
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hr in fresh TE and 20 min in H20. Plugs were equilibrated for 1 hr in the 
appropriate restriction enzyme buffer at RT. Each plug was then digested 
with 60 units of MboI for MEFs and 60 units of MboI and 60 units AluI for 
human cells overnight at 37°C. Plugs were washed with TE for 1 hr and 
equilibrated in 0.5X TBE for 30 min. 
In gel hybridization to detect telomeric DNA from MEFs 
DNA from MEFs was fractionated on a CHEF-DRII PFGE (Biorad) in a 1% 
agarose gel in 0.5X TBE for 24 hrs at 6 V/cm at 14°C. Gels were stained 
with ethidium bromide and photographed. Gels were dried and then 
prehybridized in Church Mix (0.5M Na2HPO4 pH 7.2, 1 mM EDTA, 7% 
SDS, 1% BSA) for 1 hr at 50°C. Hybridization was performed overnight at 
50°C in Church Mix with 4 ng of a γ-32P-ATP end-labeled probe, 
[CCCTAA]4 (See below for labeling protocol). The gel was washed at 55°C: 
3 times for 30 min each in 4X SSC and one time for 30 min in 4X SSC, 
0.1% SDS and exposed to a PhosphorImager screen. Subsequently, the gel 
was denatured in 0.5 M NaOH, 1.5 M NaCl for 30 min, neutralized with two 
15min washes in 0.5 M Tris-HCl pH 7.5, 3 M NaCl, prehybridized in 
Church mix for 1 hr at 55°C, and hybridized with the same probe as above 
overnight at 55°C. The gel was washed and exposed as above. 
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Southern blot to detect telomeric DNA from human cells 
DNA was separated on a 0.7% agarose gel in 0.5X TBE with ethidium 
bromide by running for 1 hr at 30 V and then running until the orange G 
front was at the bottom of the gel (approximately overnight at 45V). Gel was 
photographed. Gel was then run until the 1.3 kb marker was almost at the 
bottom of the gel and then photographed with a ruler next to the markers. 
Gel was gently shaken in Depurination solution (0.25M HCl) for 30 min, 
Denaturation solution (1.5 M NaCl; 0.5 M NaOH) for 30 min twice, and 
Neutralization solution (1 M Trish pH 7.4, 1.5M NaCl) for 30 min twice. 
Gel was then blotted onto a Hybond filter overnight in 20X SSC. Blot was 
cross-linked, rinsed in H20, and prehybridized and probed as in the in gel 
hybridization protocol above. 
γ-32P end-labeling of oligonucleotides with T4 polynucleotide kinase  
2 μl H20, 1 μl 10X T4 DNA PNK buffer (NEB), 1 μl 10 U/μl T4 DNA PNK 
(NEB), 1 μl 50 ng/μl [CCCTAA]4 oligonucleotide and 5 μl 10.0 mCi/ml γ-
32P (NEN) were mixed and incubated for 45 min at 37°C. 80 μl TES (10 mM 
Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 0.01% SDS) were added to stop the 
reaction. The probe was loaded onto a 3 ml G25 Sephadex column 
equilibrated with TNES (10 mM Tris-HCl pH 7.4, 10 mM EDTA, 100 mM 
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NaCl, 1% SDS). The column was washed with 700 μl TNES and the probe 
was eluted with 600 μl TNES. 
Metaphase spreads 
Cells were grown to approximately 40% confluence on 10 cm dishes and 
incubated for 1-2 hrs in 0.1 μg/ml colcemide (Sigma). Cells were harvested 
by trypsinization, centrifuged at 1K for 5 min, and resuspended in 0.075M 
KCL prewarmed to 37°C. Cells were incubated at 37°C for 15 min with 
occasional inversion. Cells were centrifuged at 1K for 5 min and supernatant 
was decanted. Cells were resuspended by tapping in the remaining (~200 μl) 
supernatant. 500 μl of cold 3:1 methanol:glacial acetic acid fixative was 
added dropwise while cells were mixed gently on a vortexer (<1000 rpm). 
Another 500 μl fixative was added slowly while cells were being mixed. 
Tubes were then filled to 10 mL with the fixative and stored at 4°C 
overnight or longer. Cells were centrifuged at 1K rpm for 5 min and 
supernatant was decanted. Cells were resuspended in the remaining fixative 
(~300 μl) and dropped from approximately 6 inches onto glass slides, which 
had been soaked in cold water. Slides were washed with fresh fixative and 
placed on a humidified heating block set to 70°C for 1 min. Spreading 
efficiency was checked under a light microscope. Slides were dried 
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overnight.  
Fluorescence in situ hybridization (FISH) 
Metaphases were harvested as described above. Slides were washed in PBS 
and dehydrated in an ethanol series: 5 min each 70%, 85%, 100%, and air- 
dried. Slides were incubated with FITC-TelC 5'-[CCCTAA]3-3' PNA probe 
(Applied Biosystems) in 80 μl of hybridization mix (10 mM Tris-HCl pH 
7.2, 70% deionized formamide, 0.5% blocking reagent [Boehringer 
Mannheim]) under a coverslip, placed on a 70°C heating block for 3 min, 
and then incubated in the dark for two hrs at RT. Slides were washed twice 
for 15 min each in Wash I (70% formamide, 10 mM Tris-HCl pH 7.2, 0.1% 
BSA). Slides were then washed three times for 5 min each in Wash II (0.1M 
Tris-HCl pH 7.2, 0.15M NaCl, 0.08% Tween-20). DAPI was added to the 
second wash. Slides were dehydrated in an ethanol series: 5 min each 70%, 
95%, 100%, air dried, and mounted. 
Immunofluorescence (IF) 
Cells were plated in dishes on coverslips. Cells were rinsed with PBS, fixed 
with 2% paraformaldehyde in PBS for 10 min at RT and then washed twice 
with PBS for 5 min Cells were either stored in PBS with the addition of 
0.02% azide or processed immediately. Cells were permeabilized with 0.5% 
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NP40. If extraction was desired, prior to fixation, cells were treated with 
Triton X-100 extraction buffer (0.5% Triton X-100, 20 nM HEPES-KOH 
pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose). Extracted cells were 
fixed with 3% paraformaldehyde, 2% sucrose for 10 min at RT, and washed 
twice with PBS. If extraction was performed, Triton X-100 buffer was used 
for permeabilization instead of 0.5% NP-40. After permeabilization, cells 
were washed three times with PBS and blocked with PBG (0.2% (w/v) cold 
water fish gelatin (Sigma), 0.5% (w/v) BSA (Sigma) in PBS) for 30 min at 
RT. Cells were incubated with primary antibody diluted in PBG overnight at 
4°C, washed 3 times with PBG at RT, incubated with secondary antibody 
diluted 1:250 in PBG for 45 min at RT, and washed 3 times with PBS. To 
the second PBS wash 0.1 μg/ml 4,6-diamidino-2-phenylindole (DAPI) was 
added. Coverslips were sealed onto glass sides with embedding media 
(ProLong Gold Antifade Reagent, Invitrogen). 
IF-FISH 
Cells were plated in dishes with coverslips. Cells were rinsed with PBS, 
fixed with 2% paraformaldehyde in PBS for 10 min at RT, washed twice 
with PBS for 5 min each. Cells were either stored in PBS with the addition 
of 0.02% azide or processed immediately. Coverslips were blocked for 30 
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min in blocking solution (1 mg/ml BSA, 3% goat serum, 0.1% Triton X-100, 
1 mM EDTA in PBS) and incubated for 1 hr in primary antibody diluted in 
blocking solution. Cover slips were washed 3 times 5 min each in PBS 
before incubation in secondary antibody diluted in blocking solution. Cover 
slips were washed 3 times 5 min each in PBS, dehydrated in an ethanol 
series: 5 min each 70%, 95%, 100%, and air dried. Coverslips were 
transferred (cells facing up) to glass slides and 80 μl of FITC-TelC 5'-
[CCCTAA]3-3' (Applied Biosystems) probe at 1:1000 in hybridizing 
solution (70% formamide, 0.5% blocking reagent [Boehringer Mannheim], 
10 mM Tris-HCl pH 7.2) was added. Slides were placed on a heating block 
set to 70°C for 5 min and incubated in the dark for 2 hrs – overnight. 
Coverslips were washed twice for 15 min in 70% formamide, 10 mM Tris-
HCl pH 7.2 and three times for 5 min in PBS. DAPI was added to the second 
PBS wash. Cover slips were sealed on glass slides with embedding media. 
Microscopy and image processing 
Images were captured using an Axioplan II Zeiss microscope with a 
Hamamatsu CCD digital camera using Improvision OpenLab software. 
Images were merged in OpenLab and processed with Adobe Photoshop. 
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Gel filtration 
Nuclear extract from HeLaS3 cells (10 ml, 8 mg protein/ml) was dialyzed 
overnight at 4 °C against BC150/40% glycerol (20 mM Tris (pH 7.3), 150 
mM KCl, 0.2 mM EDTA, 40% glycerol, 0.025% Nonidet P-40, and 0.5 mM 
dithiothreitol) and cleared by ultracentrifugation at 25,000 rpm for 30 min. 
The dialyzed sample (5 ml) was loaded to a Sephacryl S-300 (Amersham 
Biosciences) column (2.5 cm x 70 cm, 350 ml of packed volume) that was 
equilibrated with BC150/20% glycerol. Proteins were fractionated with 
BC150/20% glycerol at a linear flow rate of 25 ml/h, and 5-ml fractions were 
collected. Blue dextran (2 MDa) appears at the end of the void volume 
(approximately one-third of column volume), and bovine serum albumin (67 
kDa) appears at approximately two-thirds of the column volume). 
Far western analysis 
Two micrograms of purified protein derived from insect cells or bacterial 
cells, or lysate from 70 µl/500 µl induced bacterial culture were subjected to 
SDS-PAGE and then blotted onto nitrocellulose. The blots were incubated in 
blocking buffer (10 mM HEPES (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 0.1 
mM EDTA, 1 mM dithiothreitol, 10% glycerol, and 5% milk) for 3 hr at 
4°C. Following the blocking step, the blots were probed overnight at 4°C 
with 35S-labeled in vitro translated protein prepared using the TNT T7-
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coupled reticulocyte lysate system (Promega) (a 50 µl reaction mixture in 5 
ml of blocking buffer). The next morning, the blots were washed five times 
every 30 min in wash buffer (10 mM HEPES (pH 7.5), 50 mM NaCl, 10 mM 
MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, and 0.25% milk) 
and then incubated with Amplify (Amersham Biosciences) for 10 min. The 
blots were exposed on a PhosphorImager screen overnight. For the modified 
far western experiment, the blots were incubated with 4 µg of baculovirus-
derived TIN2 in 5 ml of blocking buffer after the blocking step, washed three 
times every 5 min in wash buffer, and processed as described above. 
In vitro PARP assay 
 4 µg of proteins purified from baculovirus-infected insect cells or 
Escherichia coli cells (GST-mTRF1) were incubated with with [32P]-NAD+ 
(1.3 µM) at 25 °C for 30 min. The reactions were stopped by adding ice-cold 
trichloroacetic acid to 25%. After 10 min on ice, the proteins were collected 
by microcentrifugation (10 min at 14,000 rpm at 4 °C). The pellets were 
rinsed gently with ice-cold 5% trichloroacetic acid and dissolved in sample 
loading buffer (1 M Tris-base, 12% SDS, 0.2 M dithiothreitol, and 0.1% 
bromphenol blue). The samples were separated by SDS-PAGE and analyzed 
by autoradiography and Coomassie blue staining. 
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Antibodies Used 
ID Antigen Type Applications  Origin 
371 hTRF1 
(baculo-FL) 
Rb, 
poly 
Western 1:2000 de Lange 
647 hTRF2  
(baculo-FL) 
Rb, 
poly 
Western 1:1000 Zhu/de Lange 
lab 
765 hRap1 
(baculo-FL) 
Rb, 
poly 
Western 1:2000 Li/de Lange 
864 hTIN2 
(baculo-FL) 
Rb, 
poly 
Western 1:2000 Ye/ de Lange 
1150 hTPP1 
(GST-1-250)
Rb, 
poly 
ChIP 1:350 Ye/de Lange 
978 hPOT1 
(baculo-FL)  
Rb, 
poly 
Western 1:1000 Loayza/de 
Lange 
465 hTankyrase1 
(baculo-FL) 
Rb, 
poly 
IF 1:1000 
Western 1:1000 
Ye/de Lange 
644 mTRF1 
(peptide) 
Rb, 
poly 
IF 1:2000 
ChIP 1:350 
Karlseder/de 
Lange 
1254 mTRF2 
(GST-FL) 
Rb, 
poly 
IF 1:10000 
Western 1:10000 
ChIP 1:350 
Celli/de Lange 
1252 mRap1 
(GST-FL) 
Rb, 
poly 
IF 1:10000 
Western 1:10000 
ChIP 1:350 
Celli/de Lange 
1447 mTIN2 
(GST-FL) 
Rb, 
poly 
IF 1:2000 
Western 1:2000 
ChIP 1:350 
Donigian/de 
Lange 
αmPOT1a mPOT1a 
(GST-FL) 
Mo, 
mono 
IF 1:1000 Hockemeyer/de 
Lange 
1221 mPOT1a 
(peptide) 
Rb, 
poly 
ChIP 1:350 Hockemeyer/de 
Lange 
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ID Antigen Type Applications  Origin 
1223 mPOT1b 
(peptide) 
Rb, 
poly 
ChIP 1:350 Hockemeyer/de 
Lange 
9E10 c-Myc 
peptide 
Mo, 
mono 
IF 1:1000 
Western 1:1000 
Calbiochem 
9E10 c-Myc 
peptide 
Mo, 
mono 
IF 1:5000 Sigma 
M2 Flag peptide Mo, 
mono 
IF 1:10000 
Western 1:10000 
Sigma 
HA.11 HA peptide Mo, 
mono 
Western 1:1000 Covance 
GTU88 γTubulin 
(peptide) 
Mo, 
mono 
Western 1:5000 Sigma 
α53BP1 53BP1 
(peptide) 
Rb, 
poly 
IF 1:1000 Novus 
MAT3 ATM Mo, 
mono 
Western 1:5000 Sigma 
αChk2 Chk2 Mo, 
mono 
Western 1:500 BD 
Transduction 
Lab 
Rb: Rabbit; Mo: mouse; poly: polyclonal; mono: monoclonal
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